

ASCOT Anticoagulation Statistical Analysis Report

James Totterdell Rob Mahar

2022-07-26

Table of contents

1	Introduction	16
1.1	Purpose	16
1.2	Interventions	16
1.3	Outcomes	17
1.4	Modelling	17
1.4.1	General Considerations	17
1.4.2	Further Details	18
1.5	Trial Decision Criteria	20
2	Results	21
2.1	Study Population	21
2.1.1	Summary	21
2.1.2	Analysis Sets	21
2.1.2.1	ACS-ITT	22
2.1.2.2	FAS-ITT	23
2.1.2.3	ACS-ITT-intermediate	23
2.1.2.4	ACS-ITT-aspirin	23
2.1.2.5	ACS-ITT-therapeutic	24
2.1.2.6	ACS-PP	24
2.1.3	Disposition	25
2.1.4	Intervention Allocations	31
2.1.5	Deviations	33
2.1.6	Baseline Characteristics	34
2.1.6.1	Demographics	34
2.1.6.2	Co-morbidities	36
2.1.6.3	Prognostics	37
2.1.7	Discharge Summaries	39
2.1.7.1	Drugs Received During Hospital Stay	39
2.2	Primary Outcome	40
2.2.1	Descriptive	40
2.2.2	Primary Analysis (ACS-ITT set)	44
2.2.3	Subgroups	47
2.2.3.1	Region	48
2.2.3.2	Age group	51
2.2.3.3	Days since symptom onset	53

2.2.3.4	On Room Air and Oxygen Saturation	55
2.2.3.5	Receipt of Corticosteroids	57
2.2.3.6	Receipt of Remdesivir	60
2.2.3.7	Receipt of other antiviral agent	62
2.2.3.8	D-dimer	64
2.2.3.9	Weight	67
2.2.3.10	Aspirin	68
2.2.3.11	Vaccination Status	69
2.2.4	Per-Protocol Analysis	72
2.2.5	Sensitivity Analyses	74
2.2.5.1	Sensitivity: FAS-ITT	74
2.2.5.2	Sensitivity: Concurrent Randomisations	76
2.2.5.3	Sensitivity: Missing meet primary outcome	79
2.2.5.4	Sensitivity: Missing do not meet primary outcome	81
2.2.6	Post-hoc Sensitivity Analyses	83
2.2.6.1	Prior Sensitivity - Treatment Contrasts	83
2.2.6.2	Prior Sensitivity - Weaker priors on fixed-effects	85
2.3	Secondary Outcomes	87
2.3.1	Time to clinical recovery to day 28	87
2.3.1.1	Sensitivity: Concurrent Enrolments	92
2.3.2	WHO 8-point ordinal outcome scale at day 28	98
2.3.2.1	Sensitivity: Concurrent Enrolments	101
2.3.3	All-cause mortality to day 28	105
2.3.3.1	Sensitivity: Concurrent Enrolments	107
2.3.4	Days alive and free of hospital to day 28	109
2.3.4.1	Sensitivity: Concurrent Enrolments	113
2.3.5	Days alive and free of invasive or non-invasive ventilation to day 28	117
2.3.5.1	Sensitivity: Concurrent Enrolments	120
2.3.6	Presence of patient reported shortness of breath at day 28	124
2.3.6.1	Sensitivity: Concurrent Enrolments	126
2.3.7	Modified Medical Research Council (mMRC) breathlessness scale at day 28	128
2.3.8	Quality of life as measured by EQ-5D-5L questionnaire at day 28	130
2.4	Domain Specific Outcomes	133
2.4.1	Any thrombotic event (or death) to day 28	134
3	Appendix	136
3.1	Outcomes by Model Covariates (ACS-ITT)	136
3.1.1	Primary Outcome by Model Covariates (ACS-ITT)	136
3.1.2	Time to recovery to day 28 by model covariates (ACS-ITT)	139
3.1.3	WHO outcome scale at day 28 by model covariates (ACS-ITT)	142
3.1.4	Mortality to day 28 by Model Covariates (ACS-ITT)	144
3.1.5	Days alive and free of hospital to day 28 by Model Covariates (ACS-ITT)	146

3.1.6	Days alive and free of ventilation to day 28 by Model Covariates (ACS-ITT)	148
3.1.7	Presence of patient reported shortness of breath at day 28 by model co- variates (ACS-ITT)	150
3.2	Primary Model Posterior Predictive Summaries	152
3.2.1	Primary Outcome	152
3.2.2	WHO outcome scale dat day 28	153
3.2.3	Mortality to day 28	154
3.2.4	Days alive and free of hospital to day 28	155
3.2.5	Days alive and free of ventilation to day 28	157
3.2.6	Presence of patient reported shortness of breath at day 28	159
3.2.7	mMRC Breathlessness Scale	160
3.3	Baseline Characteristics for Concurrent Sets	162
3.3.1	Demographics	162
3.3.2	Co-morbidities	165
3.3.3	Prognostics	168

List of Figures

2.1	Combined domain flowchart.	26
2.2	Overall enrolment to the anti-coagulation domain and intervention availability. Vertical dashed lines indicate timing of interim analyses.	27
2.3	Enrolment to sites in India. Vertical dashed lines indicate timing of interim analyses.	28
2.4	Enrolment to sites in Australia. Vertical dashed lines indicate timing of interim analyses.	29
2.5	Enrolment to sites in Nepal and New Zealand Vertical dashed lines indicate timing of interim analyses.	30
2.6	Intervention allocations by country.	31
2.7	Intervention allocations by calendar time (month).	31
2.8	Intervention allocations by study site.	32
2.9	Distribution of age amongst participants randomised to the anticoagulation domain.	34
2.10	Days between events for hospitalisation, randomisation, symptom onset, and first positive test.	38
2.11	Posterior densities for the treatment effect odds ratios.	45
2.12	Posterior Summaries (point - median, block - 75% CrI, line 0.95% CrI) of odds ratio for epoch and site effects for the primary outcome model fit to the ACS-ITT set.	46
2.13	Posterior densities of odds ratio for anticoagulation interventions relative to standard dose by region subgroup using ACS-ITT set.	50
2.14	Posterior densities of odds ratio for anticoagulation interventions relative to standard dose by age subgroup using ACS-ITT set.	52
2.15	Posterior densities of odds ratio for anticoagulation interventions relative to standard dose by days since first symptoms subgroup using ACS-ITT set.	54
2.16	Posterior densities of odds ratio for anticoagulation interventions relative to standard dose by room air and oxygen saturation subgroup using ACS-ITT set.	56
2.17	Posterior densities of odds ratio for anticoagulation interventions relative to standard dose by receipt of steroids subgroup using ACS-ITT set.	59
2.18	Posterior densities of odds ratio for anticoagulation interventions relative to standard dose by receipt of remdesivir subgroup using ACS-ITT set.	61
2.19	Posterior densities of odds ratio for anticoagulation interventions relative to standard dose by receipt of other antiviral subgroup using ACS-ITT set.	63

2.20	Posterior densities of odds ratio for anticoagulation interventions relative to standard dose by D-dimer subgroup using ACS-ITT set.	66
2.21	Posterior densities of odds ratio for anticoagulation interventions relative to standard dose by whether patient taking aspirin using ACS-ITT set.	69
2.22	Posterior densities of odds ratio for anticoagulation interventions relative to standard dose by patient vaccination status at baseline using ACS-ITT set. . . .	71
2.23	Posterior Summaries (point - median, block - 75% CrI, line - 95% CrI) of odds ratio for epoch and site effects for the primary outcome model fit to the ACS-PP set.	73
2.24	Posterior Summaries (point - median, block - 75% CrI, line - 95% CrI) of odds ratio for epoch and site effects for the primary outcome model fit to the FAS-ITT set.	75
2.25	Posterior Summaries (point - median, block - 75% CrI, line - 95% CrI) of odds ratio for epoch and site effects for the primary model fit to the ACS-ITT set assuming patients with missing data met the primary outcome.	80
2.26	Posterior Summaries (point - median, block - 75% CrI, line - 95% CrI) of odds ratio for epoch and site effects for the primary outcome model fit to the ACS-ITT set assuming patients with missing data did not meet the primary outcome. . .	82
2.27	Posterior Summaries (point - median, block - 0.75 CrI, line - 0.95 CrI) of odds ratio for epoch and site effects for the primary model fit to the ACS-ITT set with priors on treatment contrasts.	84
2.28	Posterior Summaries (point - median, block - 0.75 CrI, line - 0.95 CrI) of odds ratio for epoch and site effects for the primary model fit to the ACS-ITT set with weaker priors on fixed-effects.	86
2.29	Observed progression of patients with respect to death and recovery, ACS-ITT.	88
2.30	Observed progression of patients with respect to death and recovery, ACS-ITT.	88
2.31	Cause-specific baseline hazard posterior summaries, ACS-ITT.	89
2.32	Posterior Summaries (point - median, block - 75% CrI, line - 95% CrI) of odds ratio for epoch and site effects on recovery to day 28 for the outcome model fit to the ACS-ITT set.	90
2.33	Posterior Summaries (point - median, block - 75% CrI, line - 95% CrI) of odds ratio for epoch and site effects on death to day 28 for the outcome model fit to the ACS-ITT set.	91
2.34	Cause-specific baseline hazard posterior summaries, ACS-ITT-intermediate. . .	93
2.35	Cause-specific baseline hazard posterior summaries, ACS-ITT-aspirin.	95
2.36	Cause-specific baseline hazard posterior summaries, ACS-ITT-therapeutic . . .	97
2.37	Observed distribution of WHO outcome scale at day 28 by treatment group, ACS-ITT.	99
2.38	Posterior Summaries (point - median, block - 75% CrI, line - 95% CrI) of odds ratio for epoch and site effects on WHO outcome scale at day 28 for the outcome model fit to the ACS-ITT set.	100
2.39	Observed distribution of WHO outcome scale at day 28 by treatment group, ACS-ITT-intermediate.	101

2.40	Observed distribution of WHO outcome scale at day 28 by treatment group, ACS-ITT-aspirin.	102
2.41	Observed distribution of WHO outcome scale at day 28 by treatment group, ACS-ITT-therapeutic.	104
2.42	Posterior Summaries (point - median, block - 75% CrI, line - 95% CrI) of odds ratio for epoch and site effects on day 28 mortality for the primary model fit to the ACS-ITT set.	106
2.43	Observed overall distribution of days alive and free of hospital at day 28, ACS-ITT.	110
2.44	Observed distribution of days alive and free of hospital at day 28 by treatment group, ACS-ITT.	110
2.45	Observed cumulative distribution of days alive and free of hospital at day 28 by treatment group, ACS-ITT.	111
2.46	Posterior Summaries (point - median, block - 75% CrI, line - 95% CrI) of odds ratio for epoch and site effects on days alive and free of hospital to day 28 for the outcome model fit to the ACS-ITT set.	112
2.47	Observed distribution of days alive and free of hospital at day 28 by treatment group, ACS-ITT-intermediate.	113
2.48	Observed distribution of days alive and free of hospital at day 28 by treatment group, ACS-ITT-aspirin.	115
2.49	Observed distribution of days alive and free of hospital at day 28 by treatment group, ACS-ITT-therapeutic	116
2.50	Observed distribution of days alive and free of ventilation at day 28 by treatment group.	118
2.51	Posterior Summaries (point - median, block - 75% CrI, line - 95% CrI) of odds ratio for epoch and site effects on days alive and free of ventilation to day 28 for the primary model fit to the ACS-ITT set.	119
2.52	Observed distribution of days alive and free of ventilation at day 28 by treatment group, ACS-ITT-intermediate.	120
2.53	Observed distribution of days alive and free of ventilation at day 28 by treatment group, ACS-ITT-aspirin.	122
2.54	Observed distribution of days alive and free of ventilation at day 28 by treatment group, ACS-ITT-therapeutic.	123
2.55	Posterior Summaries (point - median, block - 75% CrI, line - 95% CrI) of odds ratio for epoch and site effects on day 28 shortness of breath for the primary model fit to the ACS-ITT set.	125
2.56	Posterior Summaries (point - median, block - 75% CrI, line - 95% CrI) of odds ratio for epoch and site effects on the mMRC scale at day 28 for the primary model fit to the ACS-ITT set.	129
2.57	Posterior Summaries (point - median, block - 75% CrI, line - 95% CrI) of odds ratio for epoch and site effects for any thrombotic event or death to day 28 for the primary model fit to the ACS-ITT set.	135

3.1	Proportion of participants satisfying primary outcome criteria by age at randomisation, ACS-ITT. Vertical dashed line indicates the pre-specified cut-point of 60 years of age.	136
3.2	Proportion of participants satisfying primary outcome criteria by country of randomisation, ACS-ITT.	137
3.3	Proportion of participants satisfying primary outcome criteria by country and site of randomisation, ACS-ITT.	137
3.4	Proportion of participants satisfying primary outcome criteria by calendar time (month) of randomisation, ACS-ITT.	138
3.5	Proportion of participants satisfying primary outcome criteria by days since first symptoms at randomisation, ACS-ITT. Vertical dashed line indicates the pre-specified cut-point of 7 days.	138
3.6	Time to clinical recovery to day 28 by age group at randomisation, ACS-ITT. . .	139
3.7	Time to clinical recovery to day 28 by country of randomisation, ACS-ITT. . . .	139
3.8	Time to clinical recovery to day 28 by country and site of randomisation, ACS-ITT.	140
3.9	Time to clinical recovery to day 28 by calendar time (month) of randomisation, ACS-ITT.	141
3.10	Distribution of WHO outcome scale day 28 by age at randomisation, ACS-ITT. Vertical dashed line indicates the pre-specified cut-point of 60 years of age. . . .	142
3.11	Distribution of WHO scale at day 28 by country of randomisation, ACS-ITT. . .	142
3.12	Distribution of WHO scale at day 28 by country and site of randomisation, ACS-ITT.	143
3.13	Distribution of WHO scale at day 28 by calendar time (month) of randomisation, ACS-ITT.	143
3.14	Proportion of participants who died by day 28 by age at randomisation, ACS-ITT. Vertical dashed line indicates the pre-specified cut-point of 60 years of age. . . .	144
3.15	Proportion of participants who died by day 28 by country of randomisation, ACS-ITT.	144
3.16	Proportion of participants who died by day 28 by country and site of randomisation, ACS-ITT.	145
3.17	Proportion of participants who died by day 28 by calendar time (month) of randomisation, ACS-ITT.	145
3.18	Distribution of days alive and free of hospital to day 28 by age groups, ACS-ITT.	146
3.19	Distribution of days alive and free of hospital to day 28 by country of randomisation, ACS-ITT.	146
3.20	Distribution of days alive and free of hospital to day 28 by country and site of randomisation, ACS-ITT.	147
3.21	Distribution of days alive and free of hospital to day 28 by calendar time (month) of randomisation, ACS-ITT.	147
3.22	Distribution of days alive and free of ventilation to day 28 by age groups, ACS-ITT.	148
3.23	Distribution of days alive and free of ventilation to day 28 by country of randomisation, ACS-ITT.	148

3.24	Distribution of days alive and free of ventilation to day 28 by country and site of randomisation, ACS-ITT.	149
3.25	Distribution of days alive and free of ventilation to day 28 by calendar time (month) of randomisation, ACS-ITT.	149
3.26	Proportion with patient reported shortness of breath at day 28 by age groups. .	150
3.27	Proportion with patient reported shortness of breath at day 28 by country of randomisation.	150
3.28	Proportion with patient reported shortness of breath at day 28 by country and site of randomisation.	151
3.29	Proportion with patient reported shortness of breath at day 28 by calendar time (month) of randomisation.	151
3.30	Posterior predictive distribution for primary outcome by model covariates for primary model using ACS-ITT. Red diamond indicates observed proportions. .	152
3.31	Posterior predictive distribution for WHO scale by model covariates for primary model using ACS-ITT. Red diamond indicates observed proportions. . . .	153
3.32	Posterior predictive distribution for mortality to day 28 by model covariates for primary model using ACS-ITT. Red diamond indicates observed proportions. .	154
3.33	Posterior predictive distribution for days alive and free of hospital to day 28 by model covariates (intervention, country, and epoch) for primary model using ACS-ITT. Red diamond indicates observed proportions.	155
3.34	Posterior predictive distribution for days alive and free of hospital to day 28 by model covariates (site) for primary model using ACS-ITT. Red diamond indicates observed proportions.	156
3.35	Posterior predictive distribution for days alive and free of ventilation to day 28 by model covariates (intervention, country, and epoch) for primary model using ACS-ITT. Red diamond indicates observed proportions.	157
3.36	Posterior predictive distribution for days alive and free of ventilation to day 28 by model covariates (site) for primary model using ACS-ITT. Red diamond indicates observed proportions.	158
3.37	Posterior predictive distribution for shortness of breath at day 28 by model covariates for primary model using ACS-ITT. Red diamond indicates observed proportions.	159
3.38	Posterior predictive distribution for mMRC scale by model covariates for primary model using ACS-ITT. Red diamond indicates observed proportions. . . .	160

List of Tables

2.1	Overview of the analysis sets used in this report.	22
2.2	Number and proportion of participants who were per-protocol.	33
2.3	Baseline demographics for participants randomised to the anticoagulation domain.	35
2.4	Baseline comorbidities for participants randomised to the anticoagulation domain.	36
2.6	Drugs received during hospital stay for participants randomised to the anticoagulation domain.	39
2.7	Summary of primary composite outcome by treatment group.	40
2.8	Breakdown of primary composite outcome by treatment group.	41
2.9	Breakdown of primary composite combinations by treatment group.	42
2.10	Breakdown of primary composite outcomes by treatment group and interim of enrolment.	43
2.11	Summary of domain decision quantities (relative to standard dose) for primary outcome model fit to the ACS-ITT set.	44
2.12	Summary of model parameters (fixed-effects odds-ratios) for primary outcome model fit to the ACS-ITT set.	45
2.13	Summary of other intervention contrasts for primary outcome model fit to the ACS-ITT set.	45
2.14	Summary of participant outcomes by region of enrolment in the ACS-ITT set.	48
2.15	Summary of odds ratios for treatment effects by region of enrolment in the ACS-ITT set.	49
2.16	Summary of odds ratio comparisons of treatment effects by region of enrolment in the ACS-ITT set, (reference is India).	49
2.17	Summary of participant outcomes by age group at enrolment in the ACS-ITT set.	51
2.18	Summary of odds ratios for treatment effects by age of enrolment in the ACS-ITT set.	51
2.19	Summary of odds ratio comparisons of treatment effects by age of enrolment in the ACS-ITT set.	52
2.20	Summary of participant outcomes by days since symptom onset in the ACS-ITT set.	53
2.21	Summary of odds ratios for treatment effects by DSFS of enrolment in the ACS-ITT set.	53

2.22	Summary of odds ratio comparisons of treatment effects by DSFS of enrolment in the ACS-ITT set.	54
2.23	Summary of participant outcomes by room air and oxygen saturation in the ACS-ITT set.	55
2.24	Summary of odds ratios for treatment effects by room air and oxygen saturation at enrolment in the ACS-ITT set.	55
2.25	Summary of odds ratio comparisons of treatment effects by room air and oxygen saturation at enrolment the ACS-ITT set.	56
2.26	Summary of participant outcomes by receipt of corticosteroids during index hospital stay in the ACS-ITT set.	57
2.27	Summary of odds ratios for treatment effects by receipt of corticosteroids in the ACS-ITT set.	58
2.28	Summary of odds ratio comparisons of treatment effects by receipt of corticosteroids in the ACS-ITT set.	58
2.29	Summary of participant outcomes by receipt of remdesivir during index hospital stay in the ACS-ITT set.	60
2.30	Summary of odds ratios for treatment effects by receipt of remdesivir in the ACS-ITT set.	60
2.31	Summary of odds ratio comparisons of treatment effects by receipt of remdesivir in the ACS-ITT set.	61
2.32	Summary of participant outcomes by receipt of other antiviral during index hospital stay in the ACS-ITT set.	62
2.33	Summary of odds ratios for treatment effects by receipt of other antiviral in the ACS-ITT set.	62
2.34	Summary of odds ratio comparisons of treatment effects by receipt of other antiviral in the ACS-ITT set.	63
2.35	Summary of participant outcomes by whether D-dimer was out range at enrolment in the ACS-ITT set.	64
2.36	Summary of odds ratios for treatment effects by whether D-dimer was out range at enrolment in the ACS-ITT set.	65
2.37	Summary of odds ratio comparisons of treatment effects by whether D-dimer was out range at enrolment in the ACS-ITT set.	65
2.38	Summary of participant outcomes by weight at baseline in the ACS-ITT set. . .	67
2.39	Summary of participant outcomes by whether patient was taking aspirin at baseline in the ACS-ITT set.	68
2.40	Summary of odds ratios for treatment effects by by whether patient was taking aspirin at baseline in the ACS-ITT set.	68
2.41	Summary of odds ratio comparisons of treatment effects by whether patient was taking aspirin at baseline in the ACS-ITT set.	69
2.42	Summary of participant outcomes by whether patient vaccination status at baseline in the ACS-ITT set.	70
2.43	Summary of odds ratios for treatment effects by patient vaccination status at baseline in the ACS-ITT set.	70

2.44	Summary of odds ratio comparisons of treatment effects by patient vaccination status at baseline in the ACS-ITT set.	71
2.45	Summary of primary composite outcome by treatment group for participants in ACS-PP.	72
2.46	Summary of model parameters (fixed-effects odds-ratios) for primary outcome model fit to the ACS-PP set.	72
2.47	Summary of model parameters (fixed-effects odds-ratios) for primary outcome model fit to the FAS-ITT set.	74
2.48	Summary of primary composite outcome by treatment group for participants in ACS-ITT-intermediate	76
2.49	Summary of model parameters (fixed-effects odds-ratios) for primary outcome model fit to the ACS-ITT-intermediate set.	76
2.50	Summary of primary composite outcome by treatment group for participants in ACS-ITT-aspirin.	77
2.51	Summary of model parameters (fixed-effects odds-ratios) for primary outcome model fit to the ACS-ITT-aspirin set.	77
2.52	Summary of model parameters (fixed-effects odds-ratios) for primary outcome model fit to the ACS-ITT-aspirin set.	77
2.53	Summary of primary composite outcome by treatment group for participants in ACS-ITT-therapeutic.	78
2.54	Summary of model parameters (fixed-effects odds-ratios) for primary outcome model fit to the ACS-ITT-therapeutic set.	78
2.55	Summary of model parameters (fixed-effects odds-ratios) for primary outcome model fit to the ACS-ITT-therapeutic set.	78
2.56	Summary of primary composite outcome by treatment group for participants in ACS-ITT set assuming patients with missing outcomes met the primary outcome.	79
2.57	Summary of model parameters (fixed-effects odds-ratios) for primary outcome model fit to the ACS-ITT set assuming patients with missing data met the primary outcome.	79
2.58	Summary of primary composite outcome by treatment group for participants in ACS-ITT set assuming patients with missing outcomes did not meet the primary outcome.	81
2.59	Summary of model parameters (fixed-effects odds-ratios) for primary model fit to the ACS-ITT set assuming patients with missing data did not meet the primary outcome.	81
2.60	Summary of model parameters (fixed-effects odds-ratios) for primary model fit to the ACS-ITT set with priors on treatment contrasts.	83
2.61	Summary of model parameters (fixed-effects odds-ratios) for primary model fit to the ACS-ITT set with weaker priors on fixed-effects.	85
2.62	Summary for time to recovery or death to day 28, ACS-ITT	88
2.63	Posterior summary of cause-specific odds ratios for recovery or death to day 28, ACS-ITT.	89

2.64	Summary for time to recovery or death to day 28, ACS-ITT-intermediate	92
2.65	Posterior summary of cause-specific odds ratios for recovery or death to day 28, ACS-ITT-intermediate	92
2.66	Summary for recovery or death to day 28, ACS-ITT-aspirin	94
2.67	Posterior summary of cause-specific odds ratios for recovery or death to day 28, ACS-ITT-aspirin.	94
2.68	Summary for recovery or death to day 28, ACS-ITT-therapeutic.	96
2.69	Posterior summary of cause-specific odds ratios for recovery or death to day28, ACS-ITT-therapeutic	96
2.70	Summary of WHO scale at 28 by treatment group, ACS-ITT.	98
2.71	Summary of model parameters (fixed-effects odds-ratios) for WHO outcome scale at day 28 outcome model fit to the ACS-ITT set.	98
2.72	Summary of WHO outcome scale at day 28 by treatment group, ACS-ITT-intermediate.	101
2.73	Summary of model posterior odds ratios for WHO outcome scale at day 28 by treatment group, ACS-ITT-intermediate.	102
2.74	Summary of WHO outcome scale at day 28 by treatment group, ACS-ITT-aspirin.	102
2.75	Summary of model posterior odds ratios for WHO outcome scale at day 28 by treatment group, ACS-ITT-aspirin.	103
2.76	Summary of WHO outcome scale at day 28 by treatment group, ACS-ITT-therapeutic.	103
2.77	Summary of model posterior odds ratios for WHO outcome scale at day 28 by treatment group, ACS-ITT-therapeutic.	103
2.78	Summary of mortality by day 28 by treatment group, ACS-ITT.	105
2.79	Summary of model parameters (fixed-effects odds-ratios) for mortality by day 28 primary model fit to the ACS-ITT set.	106
2.80	Summary of mortality to day 28 by treatment group, ACS-ITT-intermediate.	107
2.81	Summary of posterior odds ratios for ACS-ITT-intermediate set.	107
2.82	Summary of mortality to day 28 by treatment group, ACS-ITT-aspirin.	107
2.83	Summary of posterior odds ratios for ACS-ITT-aspirin set.	108
2.84	Summary of mortality to day 28 by treatment group, ACS-ITT-therapeutic.	108
2.85	Summary of posterior odds ratios for ACS-ITT-therapeutic. set.	108
2.86	Summary of days alive and free of hospital to day 28 by treatment group, ACS-ITT.	109
2.87	Summary of model parameters (fixed-effects odds-ratios) for days alive and free of hospital to day 28 outcome model fit to the ACS-ITT set.	109
2.88	Summary of days alive and free of hospital to day 28 by treatment group, ACS-ITT-intermediate.	113
2.89	Summary of days alive and free of hospital to day 28 by treatment group, ACS-ITT-intermediate.	114
2.90	Summary of days alive and free of hospital to day 28 by treatment group, ACS-ITT-aspirin.	114

2.91	Summary of days alive and free of hospital to day 28 by treatment group, ACS-ITT-aspirin.	114
2.92	Summary of days alive and free of hospital to day 28 by treatment group, ACS-ITT-therapeutic	115
2.93	Summary of days alive and free of hospital to day 28 by treatment group, ACS-ITT-therapeutic	115
2.94	Summary of days alive and free of ventilation to day 28 by treatment group.	117
2.95	Summary of model parameters (fixed-effects odds-ratios) for days alive and free of ventilation to day 28 primary model fit to the ACS-ITT set.	117
2.96	Summary of days alive and free of ventilation to day 28 by treatment group, ACS-ITT-intermediate.	120
2.97	Summary of days alive and free of ventilation to day 28 by treatment group, ACS-ITT-intermediate.	121
2.98	Summary of days alive and free of ventilation to day 28 by treatment group, ACS-ITT-aspirin.	121
2.99	Summary of days alive and free of ventilation to day 28 by treatment group, ACS-ITT-aspirin.	121
2.100	Summary of days alive and free of ventilation to day 28 by treatment group, ACS-ITT-therapeutic.	122
2.101	Summary of days alive and free of ventilation to day 28 by treatment group, ACS-ITT-therapeutic.	122
2.102	Summary of patient reported shortness of breath at day 28 by treatment group.	124
2.103	Summary of model parameters (fixed-effects odds-ratios) for shortness of breath at day 28 primary model fit to the ACS-ITT set.	124
2.104	Summary of shortness of breath at day 28 by treatment group, ACS-ITT-intermediate.	126
2.105	Summary of posterior odds ratios, ACS-ITT-intermediate.	126
2.106	Summary of shortness of breath at day 28 by treatment group, ACS-ITT-aspirin.	126
2.107	Summary of posterior odds ratios, ACS-ITT-aspirin.	127
2.108	Summary of shortness of breath at day 28 by treatment group, ACS-ITT-therapeutic.	127
2.109	Summary of posterior odds ratios, ACS-ITT-therapeutic.	127
2.110	mMRC breathlessness scale by anticoagulation intervention (day 28).	128
2.111	Summary of model parameters (fixed-effects odds-ratios) for the mMRC scale at day 28 primary model fit to the ACS-ITT set.	128
2.112	Prevalence of 10 most frequent, and worst, reported EQ-5D-5L profiles by treatment (day 28).	130
2.113	Distribution of responses on the EQ-5D-5L (day 28).	131
2.114	Descriptive summary of EQ-5D VAS (day 28).	132
2.115	Descriptive summary of anticoagulation-specific outcomes (thrombotic and bleeding events).	133
2.116	Summary of model parameters (fixed-effects odds-ratios) for any thrombotic event or death to day 28 for primary model fit to the ACS-ITT set.	134

3.1	Baseline demographics for participants included in ACS-ITT-aspirin.	162
3.2	Baseline demographics for participants included in ACS-ITT-therapeutic	163
3.3	Baseline demographics for participants who were not part of ACS-ITT-aspirin or ACS-ITT-therapeutic.	164
3.4	Baseline comorbidities for participants included in ACS-ITT-aspirin.	165
3.5	Baseline comorbidities for participants included in ACS-ITT-therapeutic	166
3.6	Baseline comorbidities for participants who were not part of ACS-ITT-aspirin or ACS-ITT-therapeutic.	167
3.7	Baseline prognostics for participants included in ACS-ITT-aspirin.	168
3.8	Baseline prognostics for participants included in ACS-ITT-therapeutic	169
3.9	Baseline prognostics for participants who were not part of ACS-ITT-aspirin or ACS-ITT-therapeutic.	170

1 Introduction

1.1 Purpose

The trial steering committee (TSC) closed randomisation to the anticoagulation domain on 8 April 2022. The blinded statistical analysis working group prepared a statistical analysis plan (SAP) for reporting the results of the anticoagulation domain. The unblinded team of statisticians undertook the analyses using the relevant records as extracted from the database on 2022-06-06.

This report summarises the data and results of the analyses for the anticoagulation domain. The report restricts these summaries and analyses to the interventions available in the anticoagulation domain and does not report on the interventions in the antiviral domain.

1.2 Interventions

There were four mutually exclusive interventions in the anticoagulation domain. They were:

- standard dose (control)
- intermediate dose
- standard dose plus aspirin
- therapeutic dose

For full details of the interventions, refer to the domain specific appendix to the protocol.

1.3 Outcomes

For details on the primary and secondary outcomes, refer to the core protocol. For details on the domain specific outcomes refer to the anticoagulation domain-specific appendix.

1.4 Modelling

1.4.1 General Considerations

All binary outcomes were analysed using a logistic regression model, ordinal outcomes by a cumulative logistic model with proportional odds, and the time to recovery outcome by a discrete-time competing-risk (death) time-to-event model (multinomial logistic regression). Weakly informative priors were specified for all models.

The (pre-specified) primary model for all outcomes included fixed terms for:

- anticoagulation intervention
- antiviral intervention
- intervention ineligibility
- age group (< 60 , ≥ 60 years of age)
- region of enrolment (India, Australia/New Zealand, Nepal)

Hierarchical terms were also included for:

- site of enrolment (nested within region)
- epoch of enrolment (4-week groupings)

Outcomes are coded such that an odds ratio less than 1 implies a decrease in the outcome, for example, lower odds of 28 day mortality, fewer days alive and free of hospital, etc. Therefore, depending on the outcome, an odds ratio less than 1 may imply benefit or harm, but this will be made clear for each outcome.

In general, the reference group (to which the model intercept(s) or baseline hazard applies) was taken to be a patient who was:

- randomised to the anticoagulation domain (equal weighting across all interventions)
- *not* randomised to the antiviral domain
- eligible for all anticoagulation interventions

- less than 60 years of age
- enrolled in India during the most recent epoch

Bayesian models were computed using Stan via `cmdstanr` (0.5.2 and `cmdstan` version 2.29.2) in R (4.2.1). For each model, 8 chains were used with a warm-up of 1000 iterations and sampling for 2500 iterations per chain resulting in 20,000 posterior draws per model. Standard diagnostics were assessed for each model (divergent transitions, trace plots, R-hat). If an issue was identified (e.g. divergent transitions) then the default sampling parameters may have been adjusted (e.g. increasing target acceptance rate or increasing maximum tree depth). If any convergence issues resulted for the pre-specified models, then they are reported along with the model results. If the model was amended in any way to satisfy convergence criteria (e.g. aggregation of groups, removal of model terms) then this is reported in the relevant section. Sampling was run using a different (randomly selected) random seed for each model, and these were recorded for replication.

Due to the small number of enrolments at New Zealand sites, in models where country of enrolment were included as a term, Australia and New Zealand were combined into one region. The hierarchical site effects for centres in Australia and New Zealand were nested within this joint region rather than each country individually. For models where site was included as a random effect, sites with less than 5 participants were aggregated within region into an “other sites” grouping. Similarly, for models where epoch was included, epochs with less than 10 participants were aggregated with the adjacent epoch.

Missing outcome data were not imputed for any of the models (with the exception of the deterministic imputation used in the best-case/worst-case sensitivity analyses).

1.4.2 Further Details

For all models, the primary linear predictor was the same. For a participant i with outcome y_i , their region of enrolment is denoted by $r(i) \in \{1, \dots, R\}$, their site by $s(i) \in \{1, \dots, S_{r(i)}\}$, and their epoch by $t(i) \in \{1, \dots, T\}$. Their anticoagulation design vector is denoted by x_{Ci} and their antiviral design vector by x_{Ai} , their aspirin ineligibility by e_i , and their age group by a_i , so that

$$\eta_i = x_{Ci}^\top \beta_C + x_{Ai}^\top \beta_A + \rho_{r(i)} + \xi_{r(i),s(i)} + \tau_{t(i)} + \omega_1 e_i + \omega_2 a_i,$$

was the linear predictor for the outcome for participant i .

For all models, the prior distribution on the linear components were

$$\begin{aligned}
\beta_C &\stackrel{\text{iid}}{\sim} \text{Normal}(0, 1) \\
\beta_A &\stackrel{\text{iid}}{\sim} \text{Normal}(0, 1) \\
\rho_1 = 0, \rho_r &\sim \text{Normal}(0, 1), \quad r = 2, \dots, R \\
\tau_1 = 0, \tau_t &\sim \text{Normal}(\tau_{t-1}, \sigma_\tau^2), \quad t = 2, \dots, T \\
\sigma_\tau &\sim \text{Student-}t(3, 0, 1) \\
\zeta_{r,s} &\sim \text{Normal}(0, \sigma_{\zeta_r}^2), \quad s = 1, \dots, S_r, \quad r = 1, \dots, R \\
\sigma_{\zeta_r} &\sim \text{Student-}t(3, 0, 1), \quad r = 1, \dots, R \\
\omega_1 &\sim \text{Normal}(0, 10^2) \\
\omega_2 &\sim \text{Normal}(0, 2.5^2).
\end{aligned}$$

For **binary outcomes**, $y_i \in \{0, 1\}$, the model was

$$\begin{aligned}
\pi(\eta) &= \text{logit}^{-1}(\beta_0 + \eta) \\
y_i &\sim \text{Bernoulli}(\pi(\eta_i))
\end{aligned}$$

with $\beta_0 \sim \text{Normal}(0, 2.5^2)$.

For **ordinal outcomes** with K levels, $y_i \in \{1, \dots, K\}$, the model was

$$\begin{aligned}
\pi_k(\eta) &= \begin{cases} 1 - \text{logit}^{-1}(\eta - \alpha_1) & k = 1 \\ \text{logit}^{-1}(\eta - \alpha_{k-1}) - \text{logit}^{-1}(\eta - \alpha_k) & k = 2, \dots, K-1 \\ \text{logit}^{-1}(\eta - \alpha_{K-1}) & k = K \end{cases} \\
y_i &\sim \text{Categorical}(\pi_k(\eta_i))
\end{aligned}$$

where $\alpha_k < \alpha_{k+1}$ for $k \in \{1, \dots, K-2\}$ and $\pi(0) \sim \text{Dirichlet}(2/K, \dots, 2/K)$.

For the **time-to-clinical-recovery outcome**, where $d_i \in \{1, \dots, 28\}$ denotes the day of first event (or censoring at day 28) and $m \in \{0, 1, 2\}$ indicates event types (unrecovered, recovered, died), and $y_{id} = (y_{id0}, y_{id1}, y_{id2})$ with $y_{itm} \in \{0, 1\}$ indicates the status of patient i at day $d \leq d_i$, then the model was

$$\lambda_m(d, \eta) = \frac{\exp(\alpha_{dm} + \eta_m)}{1 + \sum_{l=1}^M \exp(\alpha_{dl} + \eta_l)}, \quad m = 1, 2$$

$$y_{id} \sim \text{Multinomial} \left(1, \left(1 - \sum_{l=1}^2 \lambda_l(d, \eta_i), \lambda_1(d, \eta_i), \lambda_2(d, \eta_i) \right) \right), \quad d \leq d_i,$$

where $\eta = (\eta_1, \eta_2)$ contains the event-specific linear predictors with event-specific parameters in the same structure as previously introduced, and with priors

$$\alpha_{1m} \sim \text{Normal}(0, 10^2)$$

$$\alpha_{dm} \sim \text{Normal}(\alpha_{d-1,m}, \sigma_\alpha^2), \quad m = 1, 2,$$

on the event-specific baseline-hazard terms.

1.5 Trial Decision Criteria

As per the statistical appendix to the core protocol, the following decision quantities were of interest in the anticoagulation domain for the primary outcome model:

- **Superiority:** superiority was assessed using the posterior probability that the intervention has the lowest odds of the outcome amongst all interventions in the domain. If a single intervention had probability exceeding 0.99 superiority would be triggered for that intervention.
- **Effectiveness:** effectiveness was assessed relative to the low-dose arm as the posterior probability that the intervention reduces the odds of the outcome. If any intervention had probability exceeding 0.99 then effectiveness would be triggered for that intervention.
- **Futility:** futility was assessed relative to the low-dose arm as the posterior probability that the intervention reduces the odds of the outcome by no more than a factor of 1/1.1. If any intervention had probability exceeding 0.95 then futility would be triggered for that intervention.
- **Equivalence:** equivalence was assessed relative to the low-dose arm as the posterior probability that the intervention alters the odds of the outcome by a factor bounded by (1/1.1, 1.1).

2 Results

2.1 Study Population

2.1.1 Summary

At the time of database lock for the anticoagulation domain, 1,599 participants had been enrolled onto the study platform and 1,574 participants had been randomised to the anticoagulation domain. The first participant was randomised on 2021-02-08 and the last participant enrolled into the anticoagulation domain was randomised on 2022-03-29.

2.1.2 Analysis Sets

The primary analysis population includes all participants who were randomised to the anticoagulation domain. For the intention-to-treat (ITT) analyses, all participants randomised to the anticoagulation domain were analysed according to their assigned regimen irrespective of deviations or non-adherence. This set is referred to as the anticoagulation ITT set (ACS-ITT).

Secondary analyses expand the analysis set to include all participants randomised to the platform including those who were not randomised to the anticoagulation domain for the purpose of additional covariate information. This is referred to as the full analysis set ITT (FAS-ITT)

Per-protocol (PP) analyses restrict both of the analysis sets to only those participants who sufficiently adhered to the protocol as determined by blinded review. Participants who were not PP were excluded from these analyses, (ACS-PP and FAS-PP).

Additional analysis sets are defined for the purpose of comparing the interventions restricted to the timing of concurrent randomisation. For this purpose, the following additional analysis sets are specified:

- ACS-ITT-intermediate: ACS-ITT set restricted to only patients randomised into either standard dose or intermediate dose intervention.
- ACS-ITT-aspirin: ACS-ITT set restricted to patients randomised between 2021-02-08 (domain start) and 2021-09-10 (closure of aspirin arm) who were eligible for the standard dose plus aspirin intervention
- ACS-ITT-therapeutic: ACS-ITT set restricted to patients randomised under protocol version 5.0 (which introduced the therapeutic dose arm), noting that each site may have activated version 5.0 of the protocol at different times (or may never have activated it).

The patients included in any analysis is also conditional on the outcome: participants who were missing the outcome of interest were excluded from each set for undertaking any analyses.

Table 2.1: Overview of the analysis sets used in this report.

Name	Definition
FAS-ITT	All participants who were randomised to at least one study domain. Participants will be analysed as randomised, irrespective of withdrawal from treatment, treatment compliance, or other protocol deviations.
ACS-ITT	Subset of FAS-ITT who were randomised to the anticoagulation domain.
ACS-ITT-intermediate	Subset of ACS-ITT who were randomised to intermediate or standard dose only.
ACS-ITT-aspirin	Subset of ACS-ITT who were randomised prior to closure of the standard plus aspirin arm and were eligible for the aspirin arm.
ACS-ITT-therapeutic	Subset of ACS-ITT who were randomised after introduction of the therapeutic dose arm at a site where it became available.
ACS-PP	All participants who were randomised to the anticoagulation domain and satisfied platform, domain, and intervention protocol requirements.

2.1.2.1 ACS-ITT

The ACS-ITT population included 1,574 participants randomised to the anticoagulation domain. There were 18 participants who withdrew consent for follow-up leaving 1,556 continu-

ing participants. Of these, 30 were missing the primary outcome and 1,526 primary outcomes were observed. In the anticoagulation domain:

- 610 were assigned to **standard dose** and 596 primary outcomes were observed
- 613 were assigned to **intermediate dose** and 601 primary outcomes were observed
- 283 were assigned to **standard dose plus aspirin group** and 279 primary outcomes were observed
- 50 were assigned to **therapeutic dose** group with 50 primary outcomes observed

2.1.2.2 FAS-ITT

In this set (excluding those who withdrew consent for follow-up):

- 25 were not randomised to the anticoagulation domain
- 610 were assigned to **standard dose** and 596 primary outcomes were observed
- 613 were assigned to **intermediate dose** and 601 primary outcomes were observed
- 283 were assigned to **standard dose plus aspirin group** and 279 primary outcomes were observed
- 50 were assigned to **therapeutic dose** group with 50 primary outcomes observed

2.1.2.3 ACS-ITT-intermediate

In this set (excluding those who withdrew consent for follow-up):

- 610 were assigned to **standard dose** and 596 primary outcomes were observed
- 613 were assigned to **intermediate dose** and 601 primary outcomes were observed

2.1.2.4 ACS-ITT-aspirin

In this set (excluding those who withdrew consent for follow-up):

- 299 were assigned to **standard dose** and 292 primary outcomes were observed
- 298 were assigned to **intermediate dose** and 293 primary outcomes were observed
- 283 were assigned to **standard dose plus aspirin** and 279 primary outcomes were observed

2.1.2.5 ACS-ITT-therapeutic

In this set (excluding those who withdrew consent for follow-up):

- 79 were assigned to **standard dose** and 75 primary outcomes were observed
- 65 were assigned to **intermediate dose** and 62 primary outcomes were observed
- 50 were assigned to **therapeutic dose** and 50 primary outcomes were observed

2.1.2.6 ACS-PP

In this set (excluding those who withdrew consent for follow-up):

- 599 were assigned to **standard dose** and 586 primary outcomes were observed
- 603 were assigned to **intermediate dose** and 592 primary outcomes were observed
- 274 were assigned to **standard dose plus aspirin group** and 271 primary outcomes were observed
- 46 were assigned to **therapeutic dose** group with 46 primary outcomes observed

2.1.3 Disposition

Of the 1,574 participants randomised to the anticoagulation domain, 18 withdrew consent for follow-up leaving 1,556 participants continuing to study day 28. The analyses and summaries included in this report exclude data on participants who withdrew consent for follow-up.

Platform and domain specific flow diagrams is shown in in Figure 2.1 respectively.

Figure 2.2 presents overall platform enrolments by calendar time with timing of intervention availabilities and interim analyses. Due to an insufficient number of participants on the therapeutic anticoagulation arm, the initial allocation ratios were not changed during recruitment to the anticoagulation domain. Therefore, the only trial adaptations which occurred were the cessation of the standard dose plus aspirin intervention in the anticoagulation domain, the opening of the antiviral domain, and the introduction of the therapeutic dose intervention into the anticoagulation domain. Despite this, the timing of interim analyses are indicated on the Figures.




Figure 2.1: Combined domain flowchart.




Figure 2.2: Overall enrolment to the anti-coagulation domain and intervention availability. Vertical dashed lines indicate timing of interim analyses.




Figure 2.3: Enrolment to sites in India. Vertical dashed lines indicate timing of interim analyses.




Figure 2.4: Enrolment to sites in Australia. Vertical dashed lines indicate timing of interim analyses.




Figure 2.5: Enrolment to sites in Nepal and New Zealand Vertical dashed lines indicate timing of interim analyses.

2.1.4 Intervention Allocations

Response adaptive randomisation (RAR) was never activated in the anticoagulation domain. This was due to the therapeutic intervention never exceeding the minimum sample size of 50, and the fixed allocation to control. Therefore, target allocations to the interventions were uniform across all available interventions from trial start to trial closure. However, the available interventions did change over time and availability varied by region and site. The following figures summarise treatment allocations by country, site, and calendar time.




Figure 2.6: Intervention allocations by country.




Figure 2.7: Intervention allocations by calendar time (month).




Figure 2.8: Intervention allocations by study site.

2.1.5 Deviations

The number of participants who deviated from the per-protocol treatment is summarised in Table 2.2.

Table 2.2: Number and proportion of participants who were per-protocol.

Status	Low-dose	Intermediate-dose	Low-dose with aspirin	Therapeutic-dose
Per-protocol	599 (98)	603 (98)	274 (97)	46 (92)
Not per-protocol	11 (2)	10 (2)	9 (3)	4 (8)
Reason				
Patient Withdrawal from Domain	2 (18)	4 (40)	1 (11)	0 (0)
Protocol Deviation	9 (82)	6 (60)	8 (89)	3 (75)
Protocol Deviation & Withdrawal	0 (0)	0 (0)	0 (0)	1 (25)

2.1.6 Baseline Characteristics

The following baseline summaries exclude participants who withdrew consent for follow-up.

2.1.6.1 Demographics

The age distribution of participants are presented in Figure 2.9.




Figure 2.9: Distribution of age amongst participants randomised to the anticoagulation domain.

Baseline demographics stratified by anticoagulation interventions are reported in Table 2.3.

Table 2.3: Baseline demographics for participants randomised to the anticoagulation domain.

Variable	Anticoagulation				Overall (n = 1556)
	Low dose (n = 610)	Intermediate dose (n = 613)	Low dose with aspirin (n = 283)	Therapeutic dose (n = 50)	
Age (years), Median (IQR)	48 (37, 60)	48 (37, 61)	50 (38, 62)	58 (46, 69)	49 (37, 61)
Country					
India, n (%)	493 (81)	516 (84)	275 (97)	4 (8)	1288 (83)
Australia, n (%)	49 (8)	59 (10)	7 (2)	11 (22)	126 (8)
Nepal, n (%)	56 (9)	31 (5)	0 (0)	31 (62)	118 (8)
New Zealand, n (%)	12 (2)	7 (1)	1 (0)	4 (8)	24 (2)
Sex					
Male, n (%)	354 (58)	387 (63)	157 (55)	25 (50)	923 (59)
Female, n (%)	256 (42)	226 (37)	126 (45)	25 (50)	633 (41)
Weight (kg)					
Median, (IQR)	68 (62, 76)	70 (62, 77)	68 (62, 76)	66 (57, 80)	69 (62, 76)
Missing, n (%)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Vaccinated¹					
Yes, n (%)	191 (31)	220 (36)	42 (15)	27 (54)	480 (31)
Missing, n (%)	32 (5)	22 (4)	29 (10)	0 (0)	83 (5)
Ethnicity					
Indian, n (%)	494 (81)	518 (85)	275 (97)	4 (8)	1291 (83)
European, n (%)	21 (3)	18 (3)	4 (1)	4 (8)	47 (3)
Asian, n (%)	20 (3)	12 (2)	1 (0)	10 (20)	43 (3)
Pacific Islander, n (%)	13 (2)	12 (2)	2 (1)	3 (6)	30 (2)
Middle Eastern, n (%)	11 (2)	11 (2)	0 (0)	0 (0)	22 (1)
Maori, n (%)	3 (0)	4 (1)	0 (0)	3 (6)	10 (1)
African, n (%)	1 (0)	0 (0)	1 (0)	0 (0)	2 (0)
Aboriginal, n (%)	0 (0)	1 (0)	0 (0)	1 (2)	2 (0)
Latin American, n (%)	0 (0)	1 (0)	0 (0)	0 (0)	1 (0)
Other, n (%)	45 (7)	28 (5)	0 (0)	23 (46)	96 (6)
Unknown, n (%)	8 (1)	9 (1)	0 (0)	3 (6)	20 (1)
Smoking					
Current, n (%)	17 (3)	21 (3)	3 (1)	5 (10)	46 (3)
Former, n (%)	74 (12)	53 (9)	15 (5)	14 (28)	156 (10)
Never, n (%)	519 (85)	539 (88)	265 (94)	31 (62)	1354 (87)
Missing, n (%)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

¹ Site LUD did not have ethics approval for collection of vaccination status.

2.1.6.2 Co-morbidities

Baseline co-morbidities stratified by anticoagulation interventions are reported in Table 2.4.

Table 2.4: Baseline comorbidities for participants randomised to the anticoagulation domain.

Comorbidity	Anticoagulation				Overall (n = 1556)
	Low dose (n = 610)	Intermediate dose (n = 613)	Low dose with aspirin (n = 283)	Therapeutic dose (n = 50)	
None, n (%)	364 (60)	378 (62)	166 (59)	19 (38)	927 (60)
Hypertension, n (%)	147 (24)	140 (23)	68 (24)	14 (28)	369 (24)
Diabetes, n (%)	140 (23)	139 (23)	78 (28)	11 (22)	368 (24)
Obesity, n (%)	23 (4)	22 (4)	3 (1)	5 (10)	53 (3)
Asthma, n (%)	19 (3)	16 (3)	6 (2)	4 (8)	45 (3)
Chronic lung disease, n (%)	16 (3)	13 (2)	1 (0)	7 (14)	37 (2)
Chronic cardiac disease, n (%)	11 (2)	15 (2)	1 (0)	2 (4)	29 (2)
Obstructive sleep apnoea, n (%)	3 (0)	2 (0)	2 (1)	0 (0)	7 (0)
Iatrogenic immunosuppression, n (%)	1 (0)	6 (1)	0 (0)	0 (0)	7 (0)
Chronic kidney disease, n (%)	0 (0)	5 (1)	1 (0)	0 (0)	6 (0)
Malignant neoplasm, n (%)	1 (0)	2 (0)	0 (0)	1 (2)	4 (0)
Moderate or severe liver disease, n (%)	2 (0)	1 (0)	0 (0)	0 (0)	3 (0)
Dialysis, n (%)	0 (0)	1 (0)	0 (0)	0 (0)	1 (0)
HIV infection, n (%)	1 (0)	0 (0)	0 (0)	0 (0)	1 (0)
Dementia, n (%)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Missing, n (%)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

2.1.6.3 Prognostics

Baseline prognostics stratified by anticoagulation interventions are reported below.

Variable	Anticoagulation				Overall (n = 1556)
	Low dose (n = 610)	Intermediate dose (n = 613)	Low dose with aspirin (n = 283)	Therapeutic dose (n = 50)	
Was the patient on room air for any of the preceding 24 hours?					
Yes, n (%)	460 (75)	460 (75)	224 (79)	39 (78)	1183 (76)
Missing, n (%)	8 (1)	9 (1)	8 (3)	0 (0)	25 (2)
Was the patient's GCS < 15?					
Yes, n (%)	63 (10)	65 (11)	6 (2)	2 (4)	136 (9)
Missing, n (%)	125 (20)	135 (22)	60 (21)	0 (0)	320 (21)
Peripheral oxygen saturation (SpO2) on room air (Lowest)					
Median (IQR)	95 (94, 97)	96 (94, 97)	96 (94, 97)	94 (92, 96)	96 (94, 97)
Missing, n (%)	150 (25)	153 (25)	59 (21)	11 (22)	373 (24)
Highest respiratory rate (breaths/minute)					
Median (IQR)	22 (21, 25)	22 (21, 26)	22 (20, 26)	22 (20, 24)	22 (21, 26)
Missing, n (%)	0 (0)	1 (0)	0 (0)	0 (0)	1 (0)
Highest recorded Urea in the last 24 hours (mmol/L)					
Median (IQR)	4 (3, 5)	5 (4, 6)	4 (3, 6)	4 (3, 6)	4 (3, 6)
Missing, n (%)	30 (5)	33 (5)	16 (6)	1 (2)	80 (5)
Highest recorded CRP in the last 24 hours (mg/L)					
Median (IQR)	70 (37, 190)	75 (38, 220)	77 (44, 223)	68 (33, 129)	73 (39, 200)
Missing, n (%)	74 (12)	59 (10)	18 (6)	29 (58)	180 (12)
APTT¹					
Median (IQR)	33 (29, 36)	33 (30, 36)	32 (28, 37)	33 (28, 38)	33 (29, 36)
Missing, n (%)	430 (70)	439 (72)	195 (69)	35 (70)	1099 (71)
INR¹					
Mean (SD)	1.19 (0.39)	1.23 (0.58)	1.32 (1.34)	1.12 (0.18)	1.23 (0.72)
Missing, n (%)	103 (17)	105 (17)	47 (17)	7 (14)	262 (17)
Fibrinogen¹ (g/L)					
Mean (SD)	5.19 (2.01)	5.20 (1.60)	4.75 (1.40)	6.49 (1.52)	5.14 (1.71)
Missing, n (%)	564 (92)	555 (91)	243 (86)	42 (84)	1404 (90)
Prothrombin time¹ (sec)					
Median (IQR)	14 (13, 17)	14 (13, 17)	15 (13, 16)	13 (12, 14)	14 (13, 16)
Missing, n (%)	193 (32)	204 (33)	116 (41)	10 (20)	523 (34)
Taking aspirin					
Yes, n (%)	20 (3)	25 (4)	2 (1)	3 (6)	50 (3)

Missing, n (%)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Time from onset of symptoms to hospitalisation					
Median (IQR)	5 (3, 7)	5 (3, 6)	4 (2, 6)	4 (3, 6)	4 (3, 6)
Time from hospitalisation to randomisation					
Median (IQR)	1 (0, 2)	1 (0, 2)	1 (1, 2)	1 (1, 1)	1 (0, 2)
D-dimer					
Test performed, n(%)	494 (81)	514 (84)	247 (87)	17 (34)	1272 (82)
Out of range, n(%)	182 (37)	177 (35)	63 (26)	10 (59)	432 (34)

¹ For APTT, INR, Fibrinogen, and Prothrombin only at least one required.

The relative timing (in days) of hospitalisation, symptom onset, randomisation, and first positive test are presented in Figure 2.10.




Figure 2.10: Days between events for hospitalisation, randomisation, symptom onset, and first positive test.

2.1.7 Discharge Summaries

2.1.7.1 Drugs Received During Hospital Stay

There were 18 participants without a discharge record (due to withdrawal of consent for follow-up). For the continuing participants, the other medications received during their hospital stay are reported in Table 2.6.

Table 2.6: Drugs received during hospital stay for participants randomised to the anti-coagulation domain.

Drug received	Anticoagulation				Overall (n = 1556)
	Low dose (n = 610)	Intermediate dose (n = 613)	Low dose with aspirin (n = 283)	Therapeutic dose (n = 50)	
Antibacterial drugs, n (%)	449 (74)	443 (72)	231 (82)	38 (76)	1161 (75)
Antivirals					
No antiviral, n (%)	125 (20)	120 (20)	44 (16)	39 (78)	328 (21)
Camostat, n (%)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Favipiravir, n (%)	97 (16)	100 (16)	34 (12)	0 (0)	231 (15)
Doxycycline, n (%)	76 (12)	81 (13)	22 (8)	2 (4)	181 (12)
Ivermectin, n (%)	201 (33)	200 (33)	91 (32)	0 (0)	492 (32)
Remdesivir, n (%)	286 (47)	289 (47)	169 (60)	10 (20)	754 (48)
Other antiviral, n (%)	3 (0)	1 (0)	1 (0)	0 (0)	5 (0)
Immunomodulatory					
No immunomodulatory, n (%)	60 (10)	68 (11)	38 (13)	6 (12)	172 (11)
Anakinra, n (%)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Corticosteroids, n (%)	396 (65)	388 (63)	183 (65)	37 (74)	1004 (65)
Sarilumab, n (%)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Azithromycin, n (%)	105 (17)	108 (18)	38 (13)	5 (10)	256 (16)
Tocilizumab, n (%)	12 (2)	11 (2)	5 (2)	2 (4)	30 (2)
Baricitinib, n (%)	36 (6)	50 (8)	11 (4)	6 (12)	103 (7)
Ruxolitinib, n (%)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Tofacitinib, n (%)	11 (2)	13 (2)	5 (2)	0 (0)	29 (2)
Zinc, n (%)	388 (64)	394 (64)	173 (61)	13 (26)	968 (62)
Other immunomodulatory, n (%)	20 (3)	20 (3)	11 (4)	1 (2)	52 (3)

2.2 Primary Outcome

2.2.1 Descriptive

The primary outcome is a composite comprised of:

- day 28 mortality
- vasopressor/inotropic support within first 28 days
- new intensive respiratory support within first 28 days.

The definition also allowed for patients who had unknown day 28 status, but were discharged against medical advice (DAMA) and designated as likely to die within 28 days. However, no participants met this criteria (all cases of DAMA and likely to die within 28 days had known day 28 status).

The proportion of participants who met the primary outcome, and rates of missingness, are reported in Table 2.7. A breakdown of the composite, including missingness by component is reported in Table 2.8. Missingness was predominantly due to unknown patient status at study day 28.

A summary of the primary outcome by each of the baseline covariates pre-specified to be included in the primary model (or as pre-specified subgroup analyses) are presented in the appendix (Section 3.1.1).

Table 2.7: Summary of primary composite outcome by treatment group.

n (%)	Low dose	Intermediate dose	Low dose with aspirin	Therapeutic dose	Overall
Randomised	610	613	283	50	1556
Outcome missing	14 (2.3)	12 (2.0)	4 (1.4)	0 (0.0)	30 (1.9)
Outcome observed	596 (97.7)	601 (98.0)	279 (98.6)	50 (100.0)	1526 (98.1)
Met primary outcome	35 (5.9)	25 (4.2)	20 (7.2)	7 (14.0)	87 (5.7)

Table 2.8: Breakdown of primary composite outcome by treatment group.

Outcome	Breakdown	Low dose (n = 610)	Intermediate dose (n = 613)	Low dose with aspirin (n = 283)	Therapeutic dose (n = 50)	Overall (n = 1556)
Primary outcome						
No		561 (92)	576 (94)	259 (92)	43 (86)	1439 (92)
Yes		35 (6)	25 (4)	20 (7)	7 (14)	87 (6)
Unknown	Total	14 (2)	12 (2)	4 (1)	0 (0)	30 (2)
	Day 28 status	13 (2)	10 (2)	2 (1)	0 (0)	25 (2)
	Vasopressor/inotropes	1 (0)	2 (0)	2 (1)	0 (0)	5 (0)
Mortality						
Alive at day 28		577 (95)	588 (96)	271 (96)	44 (88)	1480 (95)
Death within 28 days	Total	19 (3)	15 (2)	10 (4)	6 (12)	50 (3)
	Prior to discharge	15 (2)	11 (2)	10 (4)	4 (8)	40 (3)
	Post-discharge	4 (1)	4 (1)	0 (0)	2 (4)	10 (1)
Unknown		14 (2)	10 (2)	2 (1)	0 (0)	26 (2)
Vasopressor/inotropes						
Not required		591 (97)	595 (97)	273 (96)	48 (96)	1507 (97)
Use within 28 days	Total	6 (1)	6 (1)	6 (2)	2 (4)	20 (1)
	Prior to discharge	5 (1)	6 (1)	6 (2)	2 (4)	19 (1)
	Post-discharge	2 (0)	0 (0)	0 (0)	1 (2)	3 (0)
Unknown		13 (2)	12 (2)	4 (1)	0 (0)	29 (2)
Ventilation						
Not required		562 (92)	579 (94)	263 (93)	43 (86)	1447 (93)
Use within 28 days	Total	35 (6)	24 (4)	18 (6)	7 (14)	84 (5)
	Prior to discharge	29 (5)	19 (3)	13 (5)	5 (10)	66 (4)
	Post-discharge	6 (1)	5 (1)	5 (2)	2 (4)	18 (1)
Unknown		13 (2)	10 (2)	2 (1)	0 (0)	25 (2)

Table 2.9: Breakdown of primary composite combinations by treatment group.

Composite outcomes, n (%)	Low dose (n = 610)	Intermediate dose (n = 613)	Low dose with aspirin (n = 283)	Therapeutic dose (n = 50)	Overall (n = 1556)
None	561 (92)	576 (94)	259 (92)	43 (86)	1439 (92)
Death + Vas./Ino. + Ventilation	6 (1)	3 (0)	3 (1)	2 (4)	14 (1)
Death + Ventilation	13 (2)	11 (2)	7 (2)	4 (8)	35 (2)
Vas./Ino. + Ventilation	0 (0)	2 (0)	1 (0)	0 (0)	3 (0)
Death	0 (0)	1 (0)	0 (0)	0 (0)	1 (0)
Vas./Ino.	0 (0)	1 (0)	2 (1)	0 (0)	3 (0)
Ventilation	16 (3)	7 (1)	7 (2)	1 (2)	31 (2)
Unknown	14 (2)	12 (2)	4 (1)	0 (0)	30 (2)

Table 2.10: Breakdown of primary composite outcomes by treatment group and interim of enrolment.

Outcome	Low	Intermediate	Low with aspirin	Therapeutic
Overall (n = 1556)				
Randomised	610	613	283	50
Known	596 (98)	601 (98)	279 (99)	50 (100)
Met primary outcome	35 (6)	25 (4)	20 (7)	7 (14)
Death	19 (3)	15 (2)	10 (4)	6 (12)
Vasopressor/inotropic support	6 (1)	6 (1)	6 (2)	2 (4)
Intensive respiratory support	35 (6)	24 (4)	18 (6)	7 (14)
Interim 1 (n = 685)				
Randomised	234	226	225	-
Known	227 (97)	222 (98)	222 (99)	-
Met primary outcome	22 (10)	15 (7)	19 (9)	-
Death	13 (6)	11 (5)	9 (4)	-
Vasopressor/inotropic support	2 (1)	3 (1)	6 (3)	-
Intensive respiratory support	22 (10)	15 (7)	17 (8)	-
Interim 2 (n = 246)				
Randomised	90	98	58	-
Known	90 (100)	97 (99)	57 (98)	-
Met primary outcome	2 (2)	3 (3)	1 (2)	-
Death	1 (1)	3 (3)	1 (2)	-
Vasopressor/inotropic support	1 (1)	0 (0)	0 (0)	-
Intensive respiratory support	2 (2)	3 (3)	1 (2)	-
Interim 3 (n = 384)				
Randomised	177	172	-	35
Known	173 (98)	167 (97)	-	35 (100)
Met primary outcome	8 (5)	4 (2)	-	6 (17)
Death	4 (2)	0 (0)	-	5 (14)
Vasopressor/inotropic support	3 (2)	2 (1)	-	2 (6)
Intensive respiratory support	8 (5)	4 (2)	-	6 (17)
Interim 4 (n = 241)				
Randomised	109	117	-	15
Known	106 (97)	115 (98)	-	15 (100)
Met primary outcome	3 (3)	3 (3)	-	1 (7)
Death	1 (1)	1 (1)	-	1 (7)
Vasopressor/inotropic support	0 (0)	1 (1)	-	0 (0)
Intensive respiratory support	3 (3)	2 (2)	-	1 (7)

2.2.2 Primary Analysis (ACS-ITT set)

The primary model was a logistic regression model adjusting for anticoagulation treatment, antiviral treatment, age (≥ 60), and region (India (ref), Australia/New Zealand, and Nepal), with random effects for site (nested within country) and epoch (calendar time 4 week intervals, most recent epoch as reference). The three most recent epochs were combined due to small numbers, and the two earliest epochs were combined for the same reason. Sites with fewer than 5 enrolments were combined within region into an “other sites” category. The primary analysis was based on the ACS-ITT set using the full model as specified in the statistical appendix to the core protocol. An odds ratio less than 1 implies a benefit (reduction in the odds of primary outcome).

In summary:

- **Model:** logistic regression
- **Terms:** anticoagulation intervention, antiviral intervention, aspirin eligibility, age group, region, site nested within region, and epoch
- **Set:** ACS-ITT

The trial decision quantities are reported in Table 2.11 and the model parameter posteriors are summarised in Table 2.12 and Figure 2.12.

Table 2.11: Summary of domain decision quantities (relative to standard dose) for primary outcome model fit to the ACS-ITT set.

Intervention	Posterior	Superior $\Pr(\text{OR} = \min(\text{OR}))$	Effective $\Pr(\text{OR} < 1)$	Futile $\Pr(\text{OR} > 1/1.1)$	Equivalent $\Pr(1/1.1 < \text{OR} < 1.1)$
Low-dose	1.00	0.08	-	-	-
Intermediate-dose	0.74 (0.43, 1.27)	0.63	0.86	0.23	0.15
Low-dose with aspirin	0.88 (0.47, 1.64)	0.27	0.65	0.47	0.22
Therapeutic-dose	2.22 (0.77, 6.20)	0.02	0.07	0.95	0.04

Table 2.12: Summary of model parameters (fixed-effects odds-ratios) for primary outcome model fit to the ACS-ITT set.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Intermediate-dose	0.74	(0.43, 1.27)	0.77 (0.22)	0.86
Low-dose with aspirin	0.88	(0.47, 1.64)	0.93 (0.30)	0.65
Therapeutic-dose	2.22	(0.77, 6.20)	2.55 (1.45)	0.07
Ineligible aspirin	2.50	(0.69, 7.93)	2.96 (1.94)	0.08
Age ≥ 60	1.88	(1.16, 3.04)	1.94 (0.49)	0.01
Australia/New Zealand	1.05	(0.23, 4.39)	1.37 (1.13)	0.47
Nepal	2.17	(0.51, 7.67)	2.66 (1.97)	0.13

Table 2.13: Summary of other intervention contrasts for primary outcome model fit to the ACS-ITT set.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Intermediate vs. low with aspirin	0.84	(0.43, 1.63)	0.89 (0.31)	0.70
Intermediate vs. therapeutic	0.33	(0.11, 0.98)	0.39 (0.23)	0.98
Low with aspirin vs. therapeutic	0.40	(0.13, 1.28)	0.47 (0.31)	0.94




Figure 2.11: Posterior densities for the treatment effect odds ratios.




Figure 2.12: Posterior Summaries (point - median, block - 75% CrI, line 0.95% CrI) of odds ratio for epoch and site effects for the primary outcome model fit to the ACS-ITT set.

2.2.3 Subgroups

The pre-specified subgroups where treatment effect heterogeneity was to be investigated were:

- region (India, Australia/New Zealand, Nepal)
- days since symptom onset (≤ 7 or > 7 days)
- age at enrolment (< 60 or ≥ 60 years of age)
- supplemental oxygen or oxygen saturation less than 94% at randomisation (yes or no)
- receipt of corticosteroid during hospital stay (yes or no)
- receipt of remdesivir during hospital stay (yes or no)
- receipt of other agent intended to be antiviral against SARS-CoV-2 during hospital stay (yes or no)

Domain-specific subgroups were additionally specified as:

- weight (< 120 or ≥ 120 kg)
- patient on aspirin at baseline (yes or no)
- D-dimer above upper limit of normal at baseline (yes or no)

For each sub-group analysis, the primary model was extended to include an interaction term between the covariate of interest and the anticoagulation interventions. In some cases, there may be no information on the subgroup-specific effect (for example, there were no participants in Nepal who were randomised to receive standard dose plus aspirin), but the results are reported in such cases noting that the posterior is driven by the prior.

In these subgroup analyses, the reference group was generally taken to be the largest subgroup and the intervention effect in this reference group has a normal prior with mean 0 and standard deviation 2.5. For each additional subgroup, the interaction between each intervention and subgroup level has a normal prior with mean 0 and standard deviation 1.

2.2.3.1 Region

A subgroup analysis of region is undertaken using the ACS-ITT set. A summary of the primary outcome by country and intervention is reported in Table 2.14. Note that no participants enrolled in Nepal or New Zealand received standard dose plus aspirin due to the timing of its removal from the domain. Despite this, an interaction term for region and standard dose plus aspirin was retained in the model, however, the associated effect (in Nepal) corresponds to the assumed prior given there is little to no data available.

Table 2.14: Summary of participant outcomes by region of enrolment in the ACS-ITT set.

Anticoagulation intervention	Patients	Known	Primary outcome
India			
Low dose	493	486	27 (6%)
Intermediate dose	516	511	20 (4%)
Low dose with aspirin	275	272	20 (7%)
Therapeutic dose	4	4	0 (0%)
Australia/New Zealand			
Low dose	61	57	4 (7%)
Intermediate dose	66	59	4 (7%)
Low dose with aspirin	8	7	0 (0%)
Therapeutic dose	15	15	1 (7%)
Nepal			
Low dose	56	53	4 (8%)
Intermediate dose	31	31	1 (3%)
Low dose with aspirin	0	0	- (-%)
Therapeutic dose	31	31	6 (19%)

Table 2.15: Summary of odds ratios for treatment effects by region of enrolment in the ACS-ITT set.

Region	Median	95% CrI	Mean (SD)	Pr(OR < 1)	Pr(OR > 1/1.1)
Intermediate					
India	0.70	(0.40, 1.22)	0.73 (0.21)	0.89	0.18
Australia/New Zealand	0.96	(0.26, 3.30)	1.17 (0.84)	0.52	0.53
Nepal	0.53	(0.11, 2.10)	0.68 (0.56)	0.81	0.23
Low with aspirin					
India	0.86	(0.46, 1.55)	0.89 (0.28)	0.70	0.42
Australia/New Zealand	0.68	(0.10, 4.29)	1.05 (1.21)	0.66	0.38
Nepal	0.84	(0.11, 6.47)	1.45 (1.98)	0.56	0.47
Therapeutic					
India	1.46	(0.37, 5.64)	1.85 (1.43)	0.29	0.75
Australia/New Zealand	1.32	(0.20, 7.51)	1.95 (2.07)	0.38	0.66
Nepal	2.76	(0.81, 9.35)	3.37 (2.36)	0.05	0.96

Table 2.16: Summary of odds ratio comparisons of treatment effects by region of enrolment in the ACS-ITT set, (reference is India).

Region	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Intermediate				
India (ref)	1.00	(1.00, 1.00)	1.00 (0.00)	0.00
Australia/New Zealand	1.37	(0.36, 4.84)	1.68 (1.21)	0.32
Nepal	0.75	(0.16, 3.01)	0.96 (0.80)	0.66
Low with aspirin				
India (ref)	1.00	(1.00, 1.00)	1.00 (0.00)	0.00
Australia/New Zealand	0.79	(0.13, 4.70)	1.19 (1.30)	0.60
Nepal	0.99	(0.14, 7.00)	1.64 (2.10)	0.50
Therapeutic				
India (ref)	1.00	(1.00, 1.00)	1.00 (0.00)	0.00
Australia/New Zealand	0.90	(0.17, 4.56)	1.26 (1.26)	0.55
Nepal	1.90	(0.45, 8.23)	2.50 (2.10)	0.19




Figure 2.13: Posterior densities of odds ratio for anticoagulation interventions relative to standard dose by region subgroup using ACS-ITT set.

2.2.3.2 Age group

A subgroup analysis of age group (< 60 or ≥ 60 years of age) was undertaken using the ACS-ITT set. A summary of the primary outcome by age group and intervention is reported in Table 2.17.

Table 2.17: Summary of participant outcomes by age group at enrolment in the ACS-ITT set.

Anticoagulation intervention	Patients	Known	Primary outcome
Age < 60 years			
Low dose	445	436	18 (4%)
Intermediate dose	436	427	15 (4%)
Low dose with aspirin	195	192	11 (6%)
Therapeutic dose	26	26	3 (12%)
Age ≥ 60 years			
Low dose	165	160	17 (11%)
Intermediate dose	177	174	10 (6%)
Low dose with aspirin	88	87	9 (10%)
Therapeutic dose	24	24	4 (17%)

Table 2.18: Summary of odds ratios for treatment effects by age of enrolment in the ACS-ITT set.

Age	Median	95% CrI	Mean (SD)	Pr(OR < 1)	Pr(OR $> 1/1.1$)
Intermediate					
Age < 60	0.79	(0.41, 1.48)	0.83 (0.28)	0.77	0.33
Age ≥ 60	0.59	(0.26, 1.32)	0.64 (0.27)	0.90	0.15
Low with aspirin					
Age < 60	0.93	(0.45, 1.87)	0.99 (0.37)	0.58	0.52
Age ≥ 60	0.73	(0.31, 1.68)	0.80 (0.36)	0.76	0.31
Therapeutic					
Age < 60	1.85	(0.57, 5.65)	2.17 (1.35)	0.15	0.89
Age ≥ 60	2.25	(0.60, 7.95)	2.76 (1.98)	0.11	0.92

Table 2.19: Summary of odds ratio comparisons of treatment effects by age of enrolment in the ACS-ITT set.

Age	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Intermediate				
Age < 60	1.00	(1.00, 1.00)	1.00 (0.00)	0.00
Age ≥ 60	0.75	(0.29, 1.93)	0.85 (0.43)	0.72
Low with aspirin				
Age < 60	1.00	(1.00, 1.00)	1.00 (0.00)	0.00
Age ≥ 60	0.79	(0.30, 2.12)	0.90 (0.48)	0.68
Therapeutic				
Age < 60	1.00	(1.00, 1.00)	1.00 (0.00)	0.00
Age ≥ 60	1.23	(0.32, 4.59)	1.53 (1.16)	0.38




Figure 2.14: Posterior densities of odds ratio for anticoagulation interventions relative to standard dose by age subgroup using ACS-ITT set.

2.2.3.3 Days since symptom onset

A subgroup analysis of days since first symptoms (DSFS) group (≤ 7 or > 7 days) was undertaken using the ACS-ITT set. A summary of the primary outcome by DSFS group and intervention is reported in Table 2.20.

Table 2.20: Summary of participant outcomes by days since symptom onset in the ACS-ITT set.

Anticoagulation intervention	Patients	Known	Primary outcome
Days since first symptoms ≤ 7			
Low dose	421	412	22 (5%)
Intermediate dose	432	426	20 (5%)
Low dose with aspirin	206	203	15 (7%)
Therapeutic dose	39	39	5 (13%)
Days since first symptoms > 7			
Low dose	189	184	13 (7%)
Intermediate dose	181	175	5 (3%)
Low dose with aspirin	77	76	5 (7%)
Therapeutic dose	11	11	2 (18%)

Table 2.21: Summary of odds ratios for treatment effects by DSFS of enrolment in the ACS-ITT set.

Days since first symptoms	Median	95% CrI	Mean (SD)	Pr(OR < 1)	Pr(OR $> 1/1.1$)
Intermediate					
Days from symptom onset ≤ 7	0.88	(0.48, 1.59)	0.92 (0.28)	0.66	0.46
Days from symptom onset > 7	0.39	(0.15, 0.99)	0.44 (0.22)	0.98	0.04
Low with aspirin					
Days from symptom onset ≤ 7	0.94	(0.48, 1.83)	1.00 (0.35)	0.57	0.54
Days from symptom onset > 7	0.61	(0.21, 1.62)	0.69 (0.37)	0.84	0.21
Therapeutic					
Days from symptom onset ≤ 7	1.94	(0.67, 5.48)	2.23 (1.25)	0.11	0.92
Days from symptom onset > 7	2.89	(0.56, 13.26)	3.88 (3.50)	0.10	0.92

Table 2.22: Summary of odds ratio comparisons of treatment effects by DSFS of enrolment in the ACS-ITT set.

Days since first symptoms	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Intermediate				
Days from symptom onset ≤ 7	1.00	(1.00, 1.00)	1.00 (0.00)	0.00
Days from symptom onset > 7	0.44	(0.15, 1.24)	0.51 (0.29)	0.94
Low with aspirin				
Days from symptom onset ≤ 7	1.00	(1.00, 1.00)	1.00 (0.00)	0.00
Days from symptom onset > 7	0.65	(0.21, 1.87)	0.75 (0.43)	0.78
Therapeutic				
Days from symptom onset ≤ 7	1.00	(1.00, 1.00)	1.00 (0.00)	0.00
Days from symptom onset > 7	1.49	(0.33, 6.30)	1.93 (1.62)	0.30




Figure 2.15: Posterior densities of odds ratio for anticoagulation interventions relative to standard dose by days since first symptoms subgroup using ACS-ITT set.

2.2.3.4 On Room Air and Oxygen Saturation

A subgroup analysis for supplemental oxygen requirement at baseline (not on room air or oxygen saturation $\geq 94\%$ or on room air and oxygen saturation $< 94\%$) was undertaken using the ACS-ITT set.

Table 2.23: Summary of participant outcomes by room air and oxygen saturation in the ACS-ITT set.

Anticoagulation intervention	Patients	Known	Primary outcome
Room air and SpO₂ $\geq 94\%$			
Low dose	350	341	11 (3%)
Intermediate dose	363	360	11 (3%)
Low dose with aspirin	171	169	7 (4%)
Therapeutic dose	24	24	1 (4%)
Not room air and SpO₂ $< 94\%$			
Low dose	252	247	24 (10%)
Intermediate dose	241	232	14 (6%)
Low dose with aspirin	104	102	13 (13%)
Therapeutic dose	26	26	6 (23%)

Table 2.24: Summary of odds ratios for treatment effects by room air and oxygen saturation at enrolment in the ACS-ITT set.

Oxygen	Median	95% CrI	Mean (SD)	Pr(OR < 1)	Pr(OR $> 1/1.1$)
Intermediate					
Room air and SpO ₂ $\geq 94\%$	0.84	(0.40, 1.76)	0.90 (0.35)	0.68	0.42
Not room air or SpO ₂ $< 94\%$ on RA	0.59	(0.29, 1.18)	0.63 (0.23)	0.93	0.11
Low with aspirin					
Room air and SpO ₂ $\geq 94\%$	0.85	(0.37, 1.91)	0.92 (0.40)	0.66	0.44
Not room air or SpO ₂ $< 94\%$ on RA	0.79	(0.36, 1.68)	0.85 (0.34)	0.73	0.36
Therapeutic					
Room air and SpO ₂ $\geq 94\%$	1.66	(0.44, 5.82)	2.03 (1.45)	0.22	0.82
Not room air or SpO ₂ $< 94\%$ on RA	2.61	(0.81, 8.14)	3.08 (1.93)	0.05	0.96

Table 2.25: Summary of odds ratio comparisons of treatment effects by room air and oxygen saturation at enrolment the ACS-ITT set.

Oxygen	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Intermediate				
Room air and SpO ₂ ≥ 94%	1.00	(1.00, 1.00)	1.00 (0.00)	0.00
Not room air or SpO ₂ < 94% on RA	0.70	(0.27, 1.76)	0.78 (0.39)	0.78
Low with aspirin				
Room air and SpO ₂ ≥ 94%	1.00	(1.00, 1.00)	1.00 (0.00)	0.00
Not room air or SpO ₂ < 94% on RA	0.93	(0.34, 2.51)	1.06 (0.57)	0.56
Therapeutic				
Room air and SpO ₂ ≥ 94%	1.00	(1.00, 1.00)	1.00 (0.00)	0.00
Not room air or SpO ₂ < 94% on RA	1.57	(0.41, 6.32)	2.02 (1.63)	0.25




Figure 2.16: Posterior densities of odds ratio for anticoagulation interventions relative to standard dose by room air and oxygen saturation subgroup using ACS-ITT set.

2.2.3.5 Receipt of Corticosteroids

A subgroup analysis by whether patient received corticosteroids (did not receive or did receive) was undertaken using the ACS-ITT set. A summary of the primary outcome by receipt of corticosteroids and intervention is reported in Table 2.26.

It is noted that this subgroup analysis was pre-specified, however receipt of corticosteroids is reported on the discharge summary and is a post-randomisation event (any receipt during their index hospital admission). Therefore, interpretation of this subgroup is challenging (more severe patients may have been more likely to receive corticosteroids, availability may be site specific, etc.).

Table 2.26: Summary of participant outcomes by receipt of corticosteroids during index hospital stay in the ACS-ITT set.

Anticoagulation intervention	Patients	Known	Primary outcome
Did not receive corticosteroids			
Low dose	214	210	8 (4%)
Intermediate dose	225	223	6 (3%)
Low dose with aspirin	100	98	4 (4%)
Therapeutic dose	13	13	1 (8%)
Received corticosteroids			
Low dose	396	386	27 (7%)
Intermediate dose	388	378	19 (5%)
Low dose with aspirin	183	181	16 (9%)
Therapeutic dose	37	37	6 (16%)

Table 2.27: Summary of odds ratios for treatment effects by receipt of corticosteroids in the ACS-ITT set.

Received corticosteroids	Median	95% CrI	Mean (SD)	Pr(OR < 1)	Pr(OR > 1/1.1)
Intermediate					
Did not receive corticosteroids	0.75	(0.32, 1.73)	0.82 (0.37)	0.75	0.32
Received corticosteroids	0.69	(0.37, 1.28)	0.73 (0.23)	0.88	0.19
Low with aspirin					
Did not receive corticosteroids	0.79	(0.30, 2.01)	0.88 (0.44)	0.69	0.38
Received corticosteroids	0.85	(0.43, 1.70)	0.91 (0.33)	0.67	0.43
Therapeutic					
Did not receive corticosteroids	1.63	(0.43, 6.02)	2.03 (1.50)	0.23	0.81
Received corticosteroids	2.35	(0.73, 7.27)	2.77 (1.73)	0.07	0.94

Table 2.28: Summary of odds ratio comparisons of treatment effects by receipt of corticosteroids in the ACS-ITT set.

Received corticosteroids	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Intermediate				
Did not receive corticosteroids	1.00	(1.00, 1.00)	1.00 (0.00)	0.00
Received corticosteroids	0.92	(0.35, 2.49)	1.05 (0.55)	0.56
Low with aspirin				
Did not receive corticosteroids	1.00	(1.00, 1.00)	1.00 (0.00)	0.00
Received corticosteroids	1.09	(0.38, 3.10)	1.25 (0.73)	0.44
Therapeutic				
Did not receive corticosteroids	1.00	(1.00, 1.00)	1.00 (0.00)	0.00
Received corticosteroids	1.44	(0.37, 5.60)	1.85 (1.46)	0.30




Figure 2.17: Posterior densities of odds ratio for anticoagulation interventions relative to standard dose by receipt of steroids subgroup using ACS-ITT set.

2.2.3.6 Receipt of Remdesivir

A subgroup analysis by whether patient received remdesivir (did not receive or did receive) was undertaken using the ACS-ITT set. A summary of the primary outcome by receipt of remdesivir and intervention is reported in Table 2.29.

Similar for corticosteroids, this subgroup analysis was pre-specified, however receipt of remdesivir is reported on the discharge summary and is a post-randomisation event.

Table 2.29: Summary of participant outcomes by receipt of remdesivir during index hospital stay in the ACS-ITT set.

Anticoagulation intervention	Patients	Known	Primary outcome
Did not receive remdesivir			
Low dose	324	315	7 (2%)
Intermediate dose	324	316	6 (2%)
Low dose with aspirin	114	112	2 (2%)
Therapeutic dose	40	40	5 (12%)
Received remdesivir			
Low dose	286	281	28 (10%)
Intermediate dose	289	285	19 (7%)
Low dose with aspirin	169	167	18 (11%)
Therapeutic dose	10	10	2 (20%)

Table 2.30: Summary of odds ratios for treatment effects by receipt of remdesivir in the ACS-ITT set.

Received remdesivir	Median	95% CrI	Mean (SD)	Pr(OR < 1)	Pr(OR > 1/1.1)
Intermediate					
Did not receive remdesivir	0.78	(0.33, 1.77)	0.85 (0.37)	0.73	0.36
Received remdesivir	0.69	(0.36, 1.29)	0.72 (0.24)	0.88	0.19
Low with aspirin					
Did not receive remdesivir	0.72	(0.24, 1.94)	0.82 (0.45)	0.73	0.33
Received remdesivir	0.84	(0.42, 1.63)	0.89 (0.31)	0.70	0.40
Therapeutic					
Did not receive remdesivir	2.27	(0.78, 6.50)	2.62 (1.52)	0.07	0.95
Received remdesivir	2.35	(0.47, 11.03)	3.20 (2.96)	0.15	0.88

Table 2.31: Summary of odds ratio comparisons of treatment effects by receipt of remdesivir in the ACS-ITT set.

Received remdesivir	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Intermediate				
Did not receive remdesivir	1.00	(1.00, 1.00)	1.00 (0.00)	0.00
Received remdesivir	0.89	(0.34, 2.36)	1.00 (0.53)	0.60
Low with aspirin				
Did not receive remdesivir	1.00	(1.00, 1.00)	1.00 (0.00)	0.00
Received remdesivir	1.16	(0.40, 3.60)	1.38 (0.89)	0.40
Therapeutic				
Did not receive remdesivir	1.00	(1.00, 1.00)	1.00 (0.00)	0.00
Received remdesivir	1.03	(0.23, 4.63)	1.37 (1.25)	0.48




Figure 2.18: Posterior densities of odds ratio for anticoagulation interventions relative to standard dose by receipt of remdesivir subgroup using ACS-ITT set.

2.2.3.7 Receipt of other antiviral agent

A subgroup analysis by whether patient received any other antiviral (other than remdesivir) (did not receive or did receive) was undertaken using the ACS-ITT set. A summary of the primary outcome by receipt of other antiviral and intervention is reported in Table 2.32.

This subgroup analysis was pre-specified, however receipt of an antiviral is reported on the discharge summary and is a post-randomisation event.

Table 2.32: Summary of participant outcomes by receipt of other antiviral during index hospital stay in the ACS-ITT set.

Anticoagulation intervention	Patients	Known	Primary outcome
Did not receive other antiviral			
Low dose	337	324	27 (8%)
Intermediate dose	340	331	23 (7%)
Low dose with aspirin	169	165	13 (8%)
Therapeutic dose	48	48	7 (15%)
Received other antiviral			
Low dose	273	272	8 (3%)
Intermediate dose	273	270	2 (1%)
Low dose with aspirin	114	114	7 (6%)
Therapeutic dose	2	2	0 (0%)

Table 2.33: Summary of odds ratios for treatment effects by receipt of other antiviral in the ACS-ITT set.

Received other antiviral	Median	95% CrI	Mean (SD)	Pr(OR < 1)	Pr(OR > 1/1.1)
Intermediate					
Did not receive other antivirals	0.79	(0.45, 1.39)	0.83 (0.24)	0.78	0.32
Received other antivirals	0.37	(0.11, 1.10)	0.43 (0.27)	0.96	0.06
Low with aspirin					
Did not receive other antivirals	0.73	(0.37, 1.40)	0.77 (0.27)	0.82	0.26
Received other antivirals	1.34	(0.49, 3.57)	1.51 (0.81)	0.28	0.78
Therapeutic					
Did not receive other antivirals	2.09	(0.77, 5.57)	2.37 (1.27)	0.07	0.95
Received other antivirals	1.80	(0.22, 13.93)	3.13 (4.40)	0.29	0.74

Table 2.34: Summary of odds ratio comparisons of treatment effects by receipt of other antiviral in the ACS-ITT set.

Received other antiviral	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Intermediate				
Did not receive other antivirals	1.00	(1.00, 1.00)	1.00 (0.00)	0.00
Received other antivirals	0.46	(0.13, 1.46)	0.54 (0.36)	0.90
Low with aspirin				
Did not receive other antivirals	1.00	(1.00, 1.00)	1.00 (0.00)	0.00
Received other antivirals	1.85	(0.61, 5.42)	2.14 (1.28)	0.13
Therapeutic				
Did not receive other antivirals	1.00	(1.00, 1.00)	1.00 (0.00)	0.00
Received other antivirals	0.86	(0.13, 5.45)	1.35 (1.61)	0.56




Figure 2.19: Posterior densities of odds ratio for anticoagulation interventions relative to standard dose by receipt of other antiviral subgroup using ACS-ITT set.

2.2.3.8 D-dimer

A subgroup analysis by whether D-dimer was out of range (D-dimer not out of range, D-dimer out of range, D-dimer unknown) was undertaken using the ACS-ITT set. A summary of the primary outcome by subgroup and intervention is reported in Table 2.35. Patients with unknown D-dimer at baseline were included as their own subgroup due to the large number with missing values.

Table 2.35: Summary of participant outcomes by whether D-dimer was out range at enrolment in the ACS-ITT set.

Anticoagulation intervention	Patients	Known	Primary outcome
D-Dimer in range			
Low dose	311	307	15 (5%)
Intermediate dose	336	332	15 (5%)
Low dose with aspirin	184	181	13 (7%)
Therapeutic dose	7	7	0 (0%)
D-Dimer out of range			
Low dose	182	179	10 (6%)
Intermediate dose	177	174	3 (2%)
Low dose with aspirin	63	62	7 (11%)
Therapeutic dose	10	10	1 (10%)
D-Dimer unknown			
Low dose	117	110	10 (9%)
Intermediate dose	100	95	7 (7%)
Low dose with aspirin	36	36	0 (0%)
Therapeutic dose	33	33	6 (18%)

Table 2.36: Summary of odds ratios for treatment effects by whether D-dimer was out range at enrolment in the ACS-ITT set.

D-dimer out of range	Median	95% CrI	Mean (SD)	Pr(OR < 1)	Pr(OR > 1/1.1)
Intermediate					
D-dimer \leq ULN	0.78	(0.42, 1.49)	0.83 (0.28)	0.77	0.32
D-dimer > ULN	0.38	(0.11, 1.12)	0.44 (0.27)	0.96	0.06
Unknown	0.89	(0.33, 2.27)	0.99 (0.51)	0.60	0.48
Low with aspirin					
D-dimer \leq ULN	0.97	(0.48, 1.91)	1.03 (0.37)	0.53	0.57
D-dimer > ULN	1.34	(0.47, 3.74)	1.54 (0.88)	0.29	0.77
Unknown	0.20	(0.04, 0.75)	0.25 (0.19)	0.99	0.01
Therapeutic					
D-dimer \leq ULN	1.34	(0.36, 4.92)	1.66 (1.22)	0.33	0.72
D-dimer > ULN	1.74	(0.23, 10.90)	2.68 (3.04)	0.29	0.75
Unknown	2.78	(0.83, 9.14)	3.34 (2.23)	0.05	0.97

Table 2.37: Summary of odds ratio comparisons of treatment effects by whether D-dimer was out range at enrolment in the ACS-ITT set.

D-dimer out of range	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Intermediate				
D-dimer \leq ULN	1.00	(1.00, 1.00)	1.00 (0.00)	0.00
D-dimer > ULN	0.48	(0.14, 1.52)	0.58 (0.37)	0.89
Unknown	1.12	(0.38, 3.17)	1.30 (0.74)	0.41
Low with aspirin				
D-dimer \leq ULN	1.00	(1.00, 1.00)	1.00 (0.00)	0.00
D-dimer > ULN	1.38	(0.45, 4.13)	1.62 (0.98)	0.28
Unknown	0.20	(0.05, 0.78)	0.26 (0.20)	0.99
Therapeutic				
D-dimer \leq ULN	1.00	(1.00, 1.00)	1.00 (0.00)	0.00
D-dimer > ULN	1.29	(0.23, 6.64)	1.82 (1.85)	0.39
Unknown	2.09	(0.50, 8.57)	2.70 (2.22)	0.16




Figure 2.20: Posterior densities of odds ratio for anticoagulation interventions relative to standard dose by D-dimer subgroup using ACS-ITT set.

2.2.3.9 Weight

Due to smaller numbers (18 participants with weight > 120 kg and zero events), this pre-specified subgroup analysis was not undertaken.

Table 2.38: Summary of participant outcomes by weight at baseline in the ACS-ITT set.

Anticoagulation intervention	Patients	Known	Primary outcome
Weight \leq 120 kg			
Low dose	599	587	35 (6%)
Intermediate dose	605	594	25 (4%)
Low dose with aspirin	282	278	20 (7%)
Therapeutic dose	49	49	7 (14%)
Weight > 120 kg			
Low dose	11	9	0 (0%)
Intermediate dose	8	7	0 (0%)
Low dose with aspirin	1	1	0 (0%)
Therapeutic dose	1	1	0 (0%)

2.2.3.10 Aspirin

A subgroup analysis by whether a patient was taking aspirin at baseline (not taking aspirin, or taking aspirin) was undertaken using the ACS-ITT set. A summary of the primary outcome by subgroup and intervention is reported in Table 2.39.

Table 2.39: Summary of participant outcomes by whether patient was taking aspirin at baseline in the ACS-ITT set.

Anticoagulation intervention	Patients	Known	Primary outcome
Patient not taking aspirin			
Low dose	590	576	30 (5%)
Intermediate dose	588	576	23 (4%)
Low dose with aspirin	281	277	19 (7%)
Therapeutic dose	47	47	7 (15%)
Patient taking aspirin			
Low dose	20	20	5 (25%)
Intermediate dose	25	25	2 (8%)
Low dose with aspirin	2	2	1 (50%)
Therapeutic dose	3	3	0 (0%)

Table 2.40: Summary of odds ratios for treatment effects by whether patient was taking aspirin at baseline in the ACS-ITT set.

Patient taking aspirin	Median	95% CrI	Mean (SD)	Pr(OR < 1)	Pr(OR > 1/1.1)
Intermediate					
Not taking aspirin	0.74	(0.43, 1.27)	0.77 (0.21)	0.86	0.22
Taking aspirin	0.57	(0.13, 2.35)	0.74 (0.60)	0.78	0.26
Low with aspirin					
Not taking aspirin	0.86	(0.47, 1.58)	0.91 (0.29)	0.68	0.44
Taking aspirin	1.23	(0.19, 7.87)	1.92 (2.26)	0.42	0.62
Therapeutic					
Not taking aspirin	2.09	(0.76, 5.59)	2.37 (1.27)	0.07	0.95
Taking aspirin	1.42	(0.20, 9.76)	2.32 (2.99)	0.36	0.67

Table 2.41: Summary of odds ratio comparisons of treatment effects by whether patient was taking aspirin at baseline in the ACS-ITT set.

Patient taking aspirin	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Intermediate				
Not taking aspirin	1.00	(1.00, 1.00)	1.00 (0.00)	0.00
Taking aspirin	0.77	(0.18, 3.10)	0.99 (0.79)	0.64
Low with aspirin				
Not taking aspirin	1.00	(1.00, 1.00)	1.00 (0.00)	0.00
Taking aspirin	1.42	(0.24, 8.47)	2.14 (2.35)	0.35
Therapeutic				
Not taking aspirin	1.00	(1.00, 1.00)	1.00 (0.00)	0.00
Taking aspirin	0.68	(0.11, 4.00)	1.02 (1.14)	0.67




Figure 2.21: Posterior densities of odds ratio for anticoagulation interventions relative to standard dose by whether patient taking aspirin using ACS-ITT set.

2.2.3.11 Vaccination Status

A post-hoc subgroup analysis by whether a patient was vaccinated or not at baseline (vaccinated, not vaccinated, unknown vaccination status) was undertaken using the ACS-ITT set.

Table 2.42: Summary of participant outcomes by whether patient vaccination status at baseline in the ACS-ITT set.

Anticoagulation intervention	Patients	Known	Primary outcome
Not vaccinated			
Low dose	387	378	24 (6%)
Intermediate dose	371	362	15 (4%)
Low dose with aspirin	212	208	14 (7%)
Therapeutic dose	23	23	4 (17%)
Vaccinated			
Low dose	191	186	3 (2%)
Intermediate dose	220	217	5 (2%)
Low dose with aspirin	42	42	1 (2%)
Therapeutic dose	27	27	3 (11%)
Unknown			
Low dose	32	32	8 (25%)
Intermediate dose	22	22	5 (23%)
Low dose with aspirin	29	29	5 (17%)
Therapeutic dose	0	0	- (-%)

Table 2.43: Summary of odds ratios for treatment effects by patient vaccination status at baseline in the ACS-ITT set.

Vaccination status	Median	95% CrI	Mean (SD)	Pr(OR < 1)	Pr(OR > 1/1.1)
Intermediate					
Not vaccinated	0.70	(0.37, 1.27)	0.73 (0.23)	0.88	0.20
Vaccinated	0.90	(0.29, 2.76)	1.06 (0.66)	0.57	0.49
Unknown	0.99	(0.30, 3.03)	1.16 (0.73)	0.51	0.56
Low with aspirin					
Not vaccinated	0.94	(0.48, 1.79)	0.99 (0.34)	0.58	0.54
Vaccinated	0.94	(0.18, 4.13)	1.26 (1.10)	0.53	0.52
Unknown	0.64	(0.21, 1.87)	0.74 (0.44)	0.79	0.26
Therapeutic					
Not vaccinated	1.94	(0.65, 5.65)	2.25 (1.34)	0.12	0.91
Vaccinated	2.79	(0.66, 11.06)	3.56 (2.83)	0.08	0.93
Unknown	1.96	(0.21, 18.16)	3.74 (5.86)	0.28	0.75

Table 2.44: Summary of odds ratio comparisons of treatment effects by patient vaccination status at baseline in the ACS-ITT set.

Vaccination status	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Intermediate				
Not vaccinated	1.00	(1.00, 1.00)	1.00 (0.00)	0.00
Vaccinated	1.30	(0.40, 4.09)	1.54 (1.00)	0.34
Unknown	1.41	(0.41, 4.63)	1.69 (1.12)	0.28
Low with aspirin				
Not vaccinated	1.00	(1.00, 1.00)	1.00 (0.00)	0.00
Vaccinated	1.01	(0.20, 4.21)	1.31 (1.10)	0.49
Unknown	0.68	(0.21, 2.17)	0.81 (0.52)	0.74
Therapeutic				
Not vaccinated	1.00	(1.00, 1.00)	1.00 (0.00)	0.00
Vaccinated	1.45	(0.35, 5.67)	1.84 (1.53)	0.31
Unknown	1.01	(0.14, 7.23)	1.66 (2.11)	0.50




Figure 2.22: Posterior densities of odds ratio for anticoagulation interventions relative to standard dose by patient vaccination status at baseline using ACS-ITT set.

2.2.4 Per-Protocol Analysis

The primary model was re-analysed using the ACS-PP set.

Table 2.45: Summary of primary composite outcome by treatment group for participants in ACS-PP.

n (%)	Low dose	Intermediate dose	Low dose with aspirin	Therapeutic dose	Overall
Randomised	599	603	274	46	1522
Outcome missing	13 (2.2)	11 (1.8)	3 (1.1)	0 (0.0)	27 (1.8)
Outcome observed	586 (97.8)	592 (98.2)	271 (98.9)	46 (100.0)	1495 (98.2)
Met primary outcome	35 (6.0)	25 (4.2)	19 (7.0)	7 (15.2)	86 (5.8)

Table 2.46: Summary of model parameters (fixed-effects odds-ratios) for primary outcome model fit to the ACS-PP set.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Intermediate	0.74	(0.42, 1.28)	0.77 (0.22)	0.86
Low with aspirin	0.85	(0.44, 1.56)	0.89 (0.29)	0.70
Therapeutic	2.52	(0.86, 7.13)	2.91 (1.67)	0.05
Ineligible aspirin	2.46	(0.66, 8.05)	2.94 (1.98)	0.09
Age \geq 60	1.87	(1.14, 3.05)	1.93 (0.49)	0.01
Australia/New Zealand	1.11	(0.24, 4.49)	1.43 (1.18)	0.44
Nepal	1.99	(0.49, 7.13)	2.47 (1.87)	0.16




Figure 2.23: Posterior Summaries (point - median, block - 75% CrI, line - 95% CrI) of odds ratio for epoch and site effects for the primary outcome model fit to the ACS-PP set.

2.2.5 Sensitivity Analyses

2.2.5.1 Sensitivity: FAS-ITT

The primary model was fit to the expanded FAS-ITT set. The model treatment effects were similar to those obtained under the ACS-ITT set.

Table 2.47: Summary of model parameters (fixed-effects odds-ratios) for primary outcome model fit to the FAS-ITT set.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Intermediate-dose	0.74	(0.43, 1.27)	0.77 (0.22)	0.86
Low-dose with aspirin	0.89	(0.48, 1.62)	0.93 (0.29)	0.64
Therapeutic-dose	2.17	(0.77, 6.00)	2.48 (1.37)	0.07
Ineligible aspirin	2.16	(0.60, 6.75)	2.55 (1.64)	0.11
Age ≥ 60	1.89	(1.18, 3.05)	1.95 (0.48)	0.01
Australia/New Zealand	1.11	(0.26, 4.56)	1.43 (1.16)	0.44
Nepal	2.19	(0.50, 7.89)	2.70 (2.00)	0.13




Figure 2.24: Posterior Summaries (point - median, block - 75% CrI, line - 95% CrI) of odds ratio for epoch and site effects for the primary outcome model fit to the FAS-ITT set.

2.2.5.2 Sensitivity: Concurrent Randomisations

In the following section, analyses are undertaken where the analysis set is restricted to participants who were randomised concurrently amongst the interventions of interest. Three sets are considered, one for each intervention. Given that the intermediate and standard dose interventions were available the entire time the anticoagulation domain was open, that analysis set is restricted to only participants randomised to one of those interventions. The other sets are determined by either a patients calendar time of randomisation or the protocol version under which they were enrolled. Given that RAR was not activated in the domain, the epoch terms are removed from these models as the intervention availability is the only factor varying the allocation probabilities. Additionally, due to smaller sample sizes, site terms and antiviral intervention terms have been dropped from the models. For the definitions of the analysis sets, refer to Section 2.1.2.

2.2.5.2.1 Intermediate dose

- **Model:** logistic regression
- **Terms:** anticoagulation intervention, age group, country
- **Set:** ACS-ITT-intermediate

Table 2.48: Summary of primary composite outcome by treatment group for participants in ACS-ITT-intermediate

n (%)	Low dose	Intermediate dose	Overall
Randomised	610	613	1223
Outcome missing	14 (2.3)	12 (2.0)	26 (2.1)
Outcome observed	596 (97.7)	601 (98.0)	1197 (97.9)
Met primary outcome	35 (5.9)	25 (4.2)	60 (5.0)

Table 2.49: Summary of model parameters (fixed-effects odds-ratios) for primary outcome model fit to the ACS-ITT-intermediate set.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Intermediate-dose	0.69	(0.41, 1.16)	0.71 (0.19)	0.92
Age ≥ 60	2.19	(1.29, 3.66)	2.26 (0.61)	0.00
Australia/New Zealand	1.39	(0.64, 2.77)	1.47 (0.55)	0.20
Nepal	1.06	(0.40, 2.38)	1.15 (0.51)	0.45

2.2.5.2.2 Standard dose plus aspirin

- **Model:** logistic regression
- **Terms:** anticoagulation intervention, age group, country
- **Set:** ACS-ITT-aspirin

A summary of the number of participants randomised and the number meeting the primary outcome are reported in Table 2.50, noting that 35 participants were ineligible for the standard dose plus aspirin intervention. The model parameter summaries are reported in Table 2.51.

Table 2.50: Summary of primary composite outcome by treatment group for participants in ACS-ITT-aspirin.

n (%)	Low dose	Intermediate dose	Low dose with aspirin	Overall
Randomised	299	298	283	880
Outcome missing	7 (2.3)	5 (1.7)	4 (1.4)	16 (1.8)
Outcome observed	292 (97.7)	293 (98.3)	279 (98.6)	864 (98.2)
Met primary outcome	21 (7.2)	16 (5.5)	20 (7.2)	57 (6.6)

Table 2.51: Summary of model parameters (fixed-effects odds-ratios) for primary outcome model fit to the ACS-ITT-aspirin set.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Intermediate-dose	0.75	(0.39, 1.45)	0.79 (0.28)	0.80
Low-dose with aspirin	0.93	(0.50, 1.73)	0.98 (0.32)	0.59
Age ≥ 60	1.91	(1.09, 3.28)	1.98 (0.57)	0.01
Australia/New Zealand	0.31	(0.07, 1.09)	0.38 (0.27)	0.97

Table 2.52: Summary of model parameters (fixed-effects odds-ratios) for primary outcome model fit to the ACS-ITT-aspirin set.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Intermediate vs. low with aspirin	0.81	(0.41, 1.58)	0.86 (0.30)	0.74

2.2.5.2.3 Therapeutic dose

- **Model:** logistic regression

- **Terms:** anticoagulation intervention, age group, country
- **Set:** ACS-ITT-therapeutic

Table 2.53: Summary of primary composite outcome by treatment group for participants in ACS-ITT-therapeutic.

n (%)	Low dose	Intermediate dose	Therapeutic dose	Overall
Randomised	79	65	50	194
Outcome missing	4 (5.1)	3 (4.6)	0 (0.0)	7 (3.6)
Outcome observed	75 (94.9)	62 (95.4)	50 (100.0)	187 (96.4)
Met primary outcome	6 (8.0)	3 (4.8)	7 (14.0)	16 (8.6)

Table 2.54: Summary of model parameters (fixed-effects odds-ratios) for primary outcome model fit to the ACS-ITT-therapeutic set.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Intermediate dose	0.65	(0.18, 2.25)	0.80 (0.57)	0.75
Therapeutic dose	1.63	(0.54, 5.07)	1.93 (1.20)	0.19
Age ≥ 60	1.88	(0.66, 5.45)	2.18 (1.27)	0.12
India	0.39	(0.08, 1.62)	0.51 (0.41)	0.90
Australia/New Zealand	1.05	(0.37, 2.84)	1.19 (0.65)	0.46

Table 2.55: Summary of model parameters (fixed-effects odds-ratios) for primary outcome model fit to the ACS-ITT-therapeutic set.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Intermediate vs. therapeutic	0.40	(0.11, 1.32)	0.48 (0.32)	0.93

2.2.5.3 Sensitivity: Missing meet primary outcome

In this analysis, patients with missing primary outcome data were assumed to have satisfied the primary outcome.

Table 2.56: Summary of primary composite outcome by treatment group for participants in ACS-ITT set assuming patients with missing outcomes met the primary outcome.

n (%)	Low dose	Intermediate dose	Low dose with aspirin	Therapeutic dose	Overall
Randomised	610	613	283	50	1556
Outcome missing	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Outcome observed	610 (100.0)	613 (100.0)	283 (100.0)	50 (100.0)	1556 (100.0)
Met primary outcome	49 (8.0)	37 (6.0)	24 (8.5)	7 (14.0)	117 (7.5)

Table 2.57: Summary of model parameters (fixed-effects odds-ratios) for primary outcome model fit to the ACS-ITT set assuming patients with missing data met the primary outcome.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Intermediate-dose	0.74	(0.46, 1.19)	0.77 (0.19)	0.89
Low-dose with aspirin	0.81	(0.46, 1.40)	0.84 (0.24)	0.77
Therapeutic-dose	1.37	(0.50, 3.51)	1.53 (0.78)	0.26
Ineligible aspirin	1.22	(0.35, 3.67)	1.42 (0.89)	0.37
Age \geq 60	1.67	(1.07, 2.59)	1.71 (0.39)	0.01
Australia/New Zealand	2.37	(0.54, 9.18)	2.99 (2.34)	0.12
Nepal	1.89	(0.43, 6.83)	2.31 (1.72)	0.18




Figure 2.25: Posterior Summaries (point - median, block - 75% CrI, line - 95% CrI) of odds ratio for epoch and site effects for the primary model fit to the ACS-ITT set assuming patients with missing data met the primary outcome.

2.2.5.4 Sensitivity: Missing do not meet primary outcome

In this analysis, patients with missing primary outcome data were assumed to have not satisfied the primary outcome conditions.

Table 2.58: Summary of primary composite outcome by treatment group for participants in ACS-ITT set assuming patients with missing outcomes did not meet the primary outcome.

n (%)	Low dose	Intermediate dose	Low dose with aspirin	Therapeutic dose	Overall
Randomised	610	613	283	50	1556
Outcome missing	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Outcome observed	610 (100.0)	613 (100.0)	283 (100.0)	50 (100.0)	1556 (100.0)
Met primary outcome	35 (5.7)	25 (4.1)	20 (7.1)	7 (14.0)	87 (5.6)

Table 2.59: Summary of model parameters (fixed-effects odds-ratios) for primary model fit to the ACS-ITT set assuming patients with missing data did not meet the primary outcome.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Intermediate-dose	0.75	(0.43, 1.30)	0.78 (0.22)	0.85
Low-dose with aspirin	0.91	(0.49, 1.67)	0.95 (0.31)	0.62
Therapeutic-dose	2.32	(0.80, 6.45)	2.66 (1.49)	0.06
Ineligible aspirin	2.83	(0.80, 9.03)	3.37 (2.19)	0.05
Age ≥ 60	1.86	(1.13, 3.04)	1.92 (0.49)	0.01
Australia/New Zealand	1.00	(0.22, 4.07)	1.29 (1.06)	0.50
Nepal	2.15	(0.49, 7.71)	2.64 (1.95)	0.14




Figure 2.26: Posterior Summaries (point - median, block - 75% CrI, line - 95% CrI) of odds ratio for epoch and site effects for the primary outcome model fit to the ACS-ITT set assuming patients with missing data did not meet the primary outcome.

2.2.6 Post-hoc Sensitivity Analyses

The following sections report on other post-hoc analyses which were undertaken, but not explicitly specified in the SAP.

2.2.6.1 Prior Sensitivity - Treatment Contrasts

The primary analysis model encodes the prior in terms of orthonormal contrasts. As a check of prior sensitivity, the primary model was re-fit with priors specified in terms of the more usual treatment contrasts.

Table 2.60: Summary of model parameters (fixed-effects odds-ratios) for primary model fit to the ACS-ITT set with priors on treatment contrasts.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Intermediate-dose	0.71	(0.42, 1.21)	0.74 (0.20)	0.90
Low-dose with aspirin	0.85	(0.46, 1.55)	0.89 (0.28)	0.70
Therapeutic-dose	2.04	(0.72, 5.39)	2.29 (1.22)	0.08
Ineligible aspirin	2.44	(0.66, 7.74)	2.89 (1.92)	0.08
Age ≥ 60	1.90	(1.17, 3.07)	1.96 (0.49)	0.01
Australia/New Zealand	1.18	(0.25, 4.84)	1.52 (1.27)	0.41
Nepal	2.10	(0.50, 7.44)	2.58 (1.93)	0.14




Figure 2.27: Posterior Summaries (point - median, block - 0.75 CrI, line - 0.95 CrI) of odds ratio for epoch and site effects for the primary model fit to the ACS-ITT set with priors on treatment contrasts.

2.2.6.2 Prior Sensitivity - Weaker priors on fixed-effects

The primary analyses model was re-fit with weaker priors ($\text{Normal}(0, 10^2)$) on the fixed-effects terms in place of the pre-specified priors.

Table 2.61: Summary of model parameters (fixed-effects odds-ratios) for primary model fit to the ACS-ITT set with weaker priors on fixed-effects.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Intermediate-dose	0.73	(0.41, 1.28)	0.76 (0.22)	0.86
Low-dose with aspirin	0.87	(0.45, 1.63)	0.91 (0.31)	0.67
Therapeutic-dose	2.72	(0.83, 8.44)	3.21 (2.02)	0.05
Ineligible aspirin	2.59	(0.69, 8.61)	3.11 (2.09)	0.07
Age ≥ 60	1.88	(1.16, 3.09)	1.94 (0.50)	0.01
Australia/New Zealand	0.80	(0.02, 12.58)	2.17 (4.58)	0.55
Nepal	3.63	(0.42, 30.30)	9.43 (119.42)	0.10




Figure 2.28: Posterior Summaries (point - median, block - 0.75 CrI, line - 0.95 CrI) of odds ratio for epoch and site effects for the primary model fit to the ACS-ITT set with weaker priors on fixed-effects.

2.3 Secondary Outcomes

For all secondary outcomes, the primary model (the model adjusting for interventions, age group, country, site, and epoch using the relevant outcome model) was fit to the ACS-ITT set. The only sensitivity analysis conducted was to repeat the analyses restricted to contemporaneous controls using a reduced model.

2.3.1 Time to clinical recovery to day 28

This section reports on the analysis for time to clinical recovery. Time to clinical recovery was taken as the first day from the index admission at which the patient had a WHO outcome score of 3 or less. For participants whose WHO outcome score was greater than 3 on the day of discharge, their day of recovery was counted as the first day after discharge, e.g. if discharged on day 7 with a daily WHO score of 4, then time to recovery was quantified as 8. Death was treated as a competing-risk to recovery. If recovery and death reportedly occurred on the same day (e.g. daily status WHO scale < 4 but discharge outcome of death on same day), then the patient was considered to have died on that day without recovery. No adjustment was made for participants who recovered but then subsequently died (i.e. only the first event was considered; any such patients were just counted as recovered on the relevant day). No allowance was made for participants who discharged against medical advice (treated as recovered following discharge).

The analysis of the time to clinical recovery to day 28 outcome used a discrete-time competing risk time-to-event model (multinomial logistic regression). The events of interest were death or recovery. Baseline cause-specific hazards were modelled separately for death and recovery with some smoothing enforced across adjacent time points via a first order random walk prior on the logit intercept terms.

This modelling approach deviated from that specified in the SAP which did not account for the competing risk of death.

- **Model:** multinomial logistic regression
- **Terms:** anticoagulation intervention, antiviral intervention, aspirin eligibility, age group, region, epoch
- **Set:** ACS-ITT

Table 2.62: Summary for time to recovery or death to day 28, ACS-ITT

Intervention	Randomised	Known	Died	Recovered	Unrecovered	TTR, Median (Q1, Q3)
Low	610	610	15 (2.5)	592 (97.0)	3 (0.5)	6 (4.00, 7.00)
Intermediate	613	613	10 (1.6)	598 (97.6)	5 (0.8)	6 (4.00, 7.00)
Low with aspirin	283	283	9 (3.2)	271 (95.8)	3 (1.1)	6 (4.00, 8.00)
Therapeutic	50	50	4 (8.0)	46 (92.0)	0 (0.0)	6 (4.25, 9.00)




Figure 2.29: Observed progression of patients with respect to death and recovery, ACS-ITT.




Figure 2.30: Observed progression of patients with respect to death and recovery, ACS-ITT.

Table 2.63: Posterior summary of cause-specific odds ratios for recovery or death to day 28, ACS-ITT.

Factor	Median	95% CrI	Mean (SD)	Pr(OR > 1)
Recovery				
Intermediate	1.13	(0.98, 1.29)	1.13 (0.08)	0.95
Low with aspirin	1.00	(0.84, 1.19)	1.00 (0.09)	0.50
Therapeutic	0.89	(0.61, 1.29)	0.90 (0.18)	0.27
Ineligible aspirin	0.77	(0.49, 1.17)	0.78 (0.17)	0.11
Age ≥ 60	0.64	(0.56, 0.74)	0.65 (0.05)	0.00
Australia/New Zealand	0.72	(0.40, 1.27)	0.75 (0.23)	0.13
Nepal	0.68	(0.23, 2.54)	0.85 (0.68)	0.24
Death				
Intermediate	0.62	(0.26, 1.47)	0.69 (0.31)	0.14
Low with aspirin	0.92	(0.37, 2.18)	1.01 (0.47)	0.42
Therapeutic	2.96	(0.75, 11.08)	3.71 (2.82)	0.94
Ineligible aspirin	4.28	(1.06, 15.46)	5.32 (4.07)	0.98
Age ≥ 60	0.89	(0.41, 1.91)	0.96 (0.39)	0.38
Australia/New Zealand	0.57	(0.12, 2.66)	0.77 (0.69)	0.23
Nepal	1.78	(0.38, 7.88)	2.37 (2.07)	0.78




Figure 2.31: Cause-specific baseline hazard posterior summaries, ACS-ITT.

Recovery




Figure 2.32: Posterior Summaries (point - median, block - 75% CrI, line - 95% CrI) of odds ratio for epoch and site effects on recovery to day 28 for the outcome model fit to the ACS-ITT set.

Death




Figure 2.33: Posterior Summaries (point - median, block - 75% CrI, line - 95% CrI) of odds ratio for epoch and site effects on death to day 28 for the outcome model fit to the ACS-ITT set.

2.3.1.1 Sensitivity: Concurrent Enrolments

2.3.1.1.1 Intermediate dose

- **Model:** multinomial logistic regression
- **Terms:** anticoagulation intervention, age group, region
- **Set:** ACS-ITT-intermediate

Table 2.64: Summary for time to recovery or death to day 28, ACS-ITT-intermediate

Intervention	Randomised	Known	Died	Recovered	Unrecovered	TTR, Median (Q1, Q3)
Low	610	610	15 (2.5)	592 (97.0)	3 (0.5)	6 (4.00, 7.00)
Intermediate	613	613	10 (1.6)	598 (97.6)	5 (0.8)	6 (4.00, 7.00)

Table 2.65: Posterior summary of cause-specific odds ratios for recovery or death to day 28, ACS-ITT-intermediate

Factor	Median	95% CrI	Mean (SD)	Pr(OR > 1)
Recovery				
Intermediate	1.14	(1.00, 1.30)	1.14 (0.08)	0.97
Age ≥ 60	0.67	(0.58, 0.78)	0.67 (0.05)	0.00
Australia/New Zealand	0.70	(0.57, 0.87)	0.71 (0.08)	0.00
Nepal	0.68	(0.53, 0.87)	0.69 (0.09)	0.00
Death				
Intermediate	0.86	(0.38, 1.89)	0.93 (0.39)	0.35
Age ≥ 60	1.05	(0.46, 2.39)	1.14 (0.50)	0.55
Australia/New Zealand	0.35	(0.09, 1.01)	0.40 (0.24)	0.03
Nepal	0.60	(0.17, 1.72)	0.69 (0.40)	0.18




Figure 2.34: Cause-specific baseline hazard posterior summaries, ACS-ITT-intermediate.

2.3.1.1.2 Standard plus aspirin

- **Model:** multinomial logistic regression
- **Terms:** anticoagulation intervention, age group, region
- **Set:** ACS-ITT-aspirin

Table 2.66: Summary for recovery or death to day 28, ACS-ITT-aspirin

Intervention	Randomised	Known	Died	Recovered	Unrecovered	TTR, Median (Q1, Q3)
Low	299	299	10 (3.3)	286 (95.7)	3 (1.0)	6 (4.00, 8.00)
Intermediate	298	298	7 (2.3)	288 (96.6)	3 (1.0)	6 (4.00, 7.00)
Low with aspirin	283	283	9 (3.2)	271 (95.8)	3 (1.1)	6 (4.00, 8.00)

Table 2.67: Posterior summary of cause-specific odds ratios for recovery or death to day 28, ACS-ITT-aspirin.

Factor	Median	95% CrI	Mean (SD)	Pr(OR > 1)
Recovery				
Intermediate	1.22	(1.01, 1.47)	1.22 (0.12)	0.98
Low with aspirin	1.02	(0.85, 1.23)	1.03 (0.10)	0.60
Age ≥ 60	0.75	(0.63, 0.89)	0.75 (0.07)	0.00
Australia/New Zealand	1.04	(0.75, 1.42)	1.05 (0.17)	0.58
Death				
Intermediate	1.00	(0.38, 2.49)	1.11 (0.55)	0.50
Low with aspirin	0.93	(0.38, 2.24)	1.02 (0.48)	0.43
Age ≥ 60	1.40	(0.63, 3.16)	1.53 (0.66)	0.79
Australia/New Zealand	0.54	(0.10, 2.30)	0.71 (0.60)	0.22




Figure 2.35: Cause-specific baseline hazard posterior summaries, ACS-ITT-aspirin.

2.3.1.1.3 Therapeutic

- **Model:** multinomial logistic regression
- **Terms:** anticoagulation intervention, age group, region
- **Set:** ACS-ITT-therapeutic

Table 2.68: Summary for recovery or death to day 28, ACS-ITT-therapeutic.

Intervention	Randomised	Known	Died	Recovered	Unrecovered	TTR, Median (Q1, Q3)
Low	79	79	1 (1.3)	78 (98.7)	0 (0.0)	6 (4.25, 9.00)
Intermediate	65	65	1 (1.5)	63 (96.9)	1 (1.5)	6 (4.00, 9.00)
Therapeutic	50	50	4 (8.0)	46 (92.0)	0 (0.0)	6 (4.25, 9.00)

Table 2.69: Posterior summary of cause-specific odds ratios for recovery or death to day28, ACS-ITT-therapeutic

Factor	Median	95% CrI	Mean (SD)	Pr(OR > 1)
Recovery				
Intermediate	0.99	(0.67, 1.45)	1.01 (0.20)	0.47
Therapeutic	0.99	(0.65, 1.49)	1.01 (0.21)	0.47
Age ≥ 60	0.47	(0.32, 0.68)	0.48 (0.09)	0.00
India	2.37	(1.27, 4.31)	2.47 (0.78)	1.00
Australia/New Zealand	1.22	(0.84, 1.76)	1.24 (0.23)	0.86
Death				
Intermediate	1.71	(0.24, 11.60)	2.76 (3.46)	0.70
Therapeutic	7.75	(1.36, 51.10)	12.26 (14.77)	0.99
Age ≥ 60	0.10	(0.01, 0.95)	0.19 (0.35)	0.02
India	0.91	(0.13, 5.90)	1.43 (1.69)	0.46
Australia/New Zealand	0.33	(0.07, 1.43)	0.44 (0.38)	0.08




Figure 2.36: Cause-specific baseline hazard posterior summaries, ACS-ITT-therapeutic

2.3.2 WHO 8-point ordinal outcome scale at day 28

This section reports on the analysis of the secondary outcome: WHO outcome scale at day 28. The model is coded so that an odds ratio less than 1 implies a benefit (reduction in odds of having a higher WHO score at day 28).

- **Model:** cumulative logistic (ordinal) regression assuming proportional odds
- **Terms:** anticoagulation intervention, antiviral intervention, aspirin eligibility, age group, region, site nested within region, and epoch.
- **Set:** ACS-ITT

Table 2.70 presents the number of participants where the outcome was observed by the allocated anticoagulation arm. The model parameters (odds ratios) are summarised in Table 2.71 for the fixed-effect terms and in Figure 2.38 for the site and epoch specific terms.

Table 2.70: Summary of WHO scale at 28 by treatment group, ACS-ITT.

Anticoagulation intervention	Patients	Known	Deaths	Hospitalised	WHO, Median (Q1, Q3)
Low-dose	610	596	19 (3%)	7 (1%)	1 (1, 2)
Intermediate-dose	613	603	15 (2%)	5 (1%)	1 (1, 2)
Low-dose with aspirin	283	281	10 (4%)	5 (2%)	1 (1, 2)
Therapeutic-dose	50	50	6 (12%)	1 (2%)	1 (1, 2)
Overall	1556	1530	50 (3%)	18 (1%)	1 (1, 2)

Table 2.71: Summary of model parameters (fixed-effects odds-ratios) for WHO outcome scale at day 28 outcome model fit to the ACS-ITT set.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Intermediate	0.81	(0.61, 1.07)	0.82 (0.12)	0.93
Low with aspirin	0.76	(0.53, 1.09)	0.77 (0.14)	0.93
Therapeutic	1.53	(0.77, 3.06)	1.63 (0.60)	0.12
Ineligible aspirin	1.72	(0.78, 3.77)	1.86 (0.77)	0.09
Age \geq 60	2.47	(1.90, 3.27)	2.50 (0.35)	0.00
Australia/New Zealand	1.37	(0.42, 4.25)	1.62 (1.02)	0.30
Nepal	0.73	(0.23, 2.46)	0.88 (0.63)	0.71




Figure 2.37: Observed distribution of WHO outcome scale at day 28 by treatment group, ACS-ITT.




Figure 2.38: Posterior Summaries (point - median, block - 75% CrI, line - 95% CrI) of odds ratio for epoch and site effects on WHO outcome scale at day 28 for the outcome model fit to the ACS-ITT set.

2.3.2.1 Sensitivity: Concurrent Enrolments

2.3.2.1.1 Intermediate dose

- **Model:** cumulative logistic (ordinal) regression assuming proportional odds
- **Terms:** anticoagulation intervention, age group, region
- **Set:** ACS-ITT-intermediate

Table 2.72: Summary of WHO outcome scale at day 28 by treatment group, ACS-ITT-intermediate.

Anticoagulation intervention	Patients	Known	Deaths	Hospitalised	WHO, Median (Q1, Q3)
Low-dose	610	596	19 (3%)	7 (1%)	1 (1, 2)
Intermediate-dose	613	603	15 (2%)	5 (1%)	1 (1, 2)
Overall	1223	1199	34 (3%)	12 (1%)	1 (1, 2)




Figure 2.39: Observed distribution of WHO outcome scale at day 28 by treatment group, ACS-ITT-intermediate.

Table 2.73: Summary of model posterior odds ratios for WHO outcome scale at day 28 by treatment group, ACS-ITT-intermediate.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Intermediate	0.83	(0.64, 1.08)	0.84 (0.11)	0.92
Age ≥ 60	2.77	(2.11, 3.65)	2.80 (0.39)	0.00
Australia/New Zealand	2.21	(1.51, 3.23)	2.25 (0.44)	0.00
Nepal	0.56	(0.31, 0.97)	0.59 (0.17)	0.98

2.3.2.1.2 Standard dose plus aspirin

- **Model:** cumulative logistic (ordinal) regression assuming proportional odds
- **Terms:** anticoagulation intervention, age group, region
- **Set:** ACS-ITT-aspirin

Table 2.74: Summary of WHO outcome scale at day 28 by treatment group, ACS-ITT-aspirin.

Anticoagulation intervention	Patients	Known	Deaths	Hospitalised	WHO, Median (Q1, Q3)
Low-dose	299	291	11 (4%)	5 (2%)	1 (1, 2)
Intermediate-dose	298	293	12 (4%)	3 (1%)	1 (1, 2)
Low-dose with aspirin	283	281	10 (4%)	5 (2%)	1 (1, 2)
Overall	880	865	33 (4%)	13 (2%)	1 (1, 2)




Figure 2.40: Observed distribution of WHO outcome scale at day 28 by treatment group, ACS-ITT-aspirin.

Table 2.75: Summary of model posterior odds ratios for WHO outcome scale at day 28 by treatment group, ACS-ITT-aspirin.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Intermediate	0.86	(0.61, 1.22)	0.87 (0.16)	0.80
Low with aspirin	0.73	(0.51, 1.05)	0.74 (0.14)	0.96
Age \geq 60	2.10	(1.53, 2.88)	2.13 (0.34)	0.00
Australia/New Zealand	0.95	(0.52, 1.68)	0.99 (0.30)	0.56

2.3.2.1.3 Therapeutic dose

- **Model:** cumulative logistic (ordinal) regression assuming proportional odds
- **Terms:** anticoagulation intervention, age group, region
- **Set:** ACS-ITT-therapeutic

Note: the reference region was switched to Nepal for this model due to small numbers in India.

Table 2.76: Summary of WHO outcome scale at day 28 by treatment group, ACS-ITT-therapeutic.

Anticoagulation intervention	Patients	Known	Deaths	Hospitalised	WHO, Median (Q1, Q3)
Low-dose	79	75	3 (4%)	1 (1%)	1 (1, 2)
Intermediate-dose	65	63	1 (2%)	1 (2%)	1 (1, 2)
Therapeutic-dose	50	50	6 (12%)	1 (2%)	1 (1, 2)
Overall	194	188	10 (5%)	3 (2%)	1 (1, 2)

Table 2.77: Summary of model posterior odds ratios for WHO outcome scale at day 28 by treatment group, ACS-ITT-therapeutic.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Intermediate	0.49	(0.22, 1.03)	0.53 (0.21)	0.97
Therapeutic	1.08	(0.50, 2.32)	1.16 (0.47)	0.42
Age \geq 60	3.27	(1.68, 6.45)	3.48 (1.24)	0.00
India	0.99	(0.37, 2.57)	1.11 (0.58)	0.51
Australia/New Zealand	3.87	(2.02, 7.63)	4.12 (1.45)	0.00




Figure 2.41: Observed distribution of WHO outcome scale at day 28 by treatment group, ACS-ITT-therapeutic.

2.3.3 All-cause mortality to day 28

This section reports on the analysis of the secondary outcome: all-cause mortality to day 28. For this outcome, participants who died within 28 days were coded to have a value of 1, and those who did not, to have a value of 0. The model is coded so that an odds ratio less than 1 implies a benefit (reduction in odds of death by day 28).

- **Model:** logistic regression
- **Terms:** anticoagulation intervention, antiviral intervention, aspirin eligibility, age group, region, site nested within region, and epoch.
- **Set:** ACS-ITT

Table 2.78 presents the number of participants where the outcome was observed by the allocated anticoagulation arm. The model parameters (odds ratios) are summarised in Table 2.79 for the fixed-effect terms and in Figure 2.42 for the site and epoch specific terms.

The proportion who had died by day 28 was 3.3% (50 / 1530) amongst all randomised participants. Compared with standard dose, the median adjusted odds ratios (95% CrI) from the primary model were: 0.84 (0.41, 1.67) for intermediate dose, 0.82 (0.36, 1.81) for standard dose plus aspirin, and 3.16 (0.95, 10.5) for therapeutic dose. The corresponding posterior probabilities for effectiveness were 0.69, 0.69 and 0.03 respectively.

Table 2.78: Summary of mortality by day 28 by treatment group, ACS-ITT.

n (%)	Patients	Known	Missing	Died by day 28
Low dose	610	596 (97.7)	14 (2.3)	19 (3.2)
Intermediate dose	613	603 (98.4)	10 (1.6)	15 (2.5)
Low dose with aspirin	283	281 (99.3)	2 (0.7)	10 (3.6)
Therapeutic dose	50	50 (100.0)	0 (0.0)	6 (12.0)
Overall	1556	1530 (98.3)	26 (1.7)	50 (3.3)

Table 2.79: Summary of model parameters (fixed-effects odds-ratios) for mortality by day 28 primary model fit to the ACS-ITT set.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Intermediate	0.84	(0.42, 1.70)	0.89 (0.33)	0.69
Low with aspirin	0.82	(0.35, 1.84)	0.89 (0.39)	0.69
Therapeutic	3.17	(0.96, 10.05)	3.77 (2.43)	0.03
Ineligible aspirin	4.73	(1.23, 16.96)	5.82 (4.21)	0.01
Age ≥ 60	2.08	(1.12, 3.86)	2.19 (0.72)	0.01
Australia/New Zealand	0.62	(0.13, 2.75)	0.82 (0.73)	0.73
Nepal	2.85	(0.57, 11.08)	3.61 (2.87)	0.09




Figure 2.42: Posterior Summaries (point - median, block - 75% CrI, line - 95% CrI) of odds ratio for epoch and site effects on day 28 mortality for the primary model fit to the ACS-ITT set.

2.3.3.1 Sensitivity: Concurrent Enrolments

2.3.3.1.1 Intermediate dose

- **Model:** logistic regression
- **Terms:** anticoagulation intervention, age group, region
- **Set:** ACS-ITT-intermediate

Table 2.80: Summary of mortality to day 28 by treatment group, ACS-ITT-intermediate.

n (%)	Patients	Known	Missing	Died by day 28
Low dose	610	596 (97.7)	14 (2.3)	19 (3.2)
Intermediate dose	613	603 (98.4)	10 (1.6)	15 (2.5)
Overall	1223	1199 (98.0)	24 (2.0)	34 (2.8)

Table 2.81: Summary of posterior odds ratios for ACS-ITT-intermediate set.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Intermediate	0.78	(0.39, 1.54)	0.83 (0.29)	0.76
Age ≥ 60	2.84	(1.44, 5.62)	3.01 (1.08)	0.00
Australia/New Zealand	0.46	(0.12, 1.41)	0.54 (0.34)	0.91
Nepal	1.31	(0.46, 3.22)	1.45 (0.72)	0.30

2.3.3.1.2 Standard dose plus aspirin

- **Model:** logistic regression
- **Terms:** anticoagulation intervention, age group, region
- **Set:** ACS-ITT-aspirin

Table 2.82: Summary of mortality to day 28 by treatment group, ACS-ITT-aspirin.

n (%)	Patients	Known	Missing	Died by day 28
Low dose	299	291 (97.3)	8 (2.7)	11 (3.8)
Intermediate dose	298	293 (98.3)	5 (1.7)	12 (4.1)
Low dose with aspirin	283	281 (99.3)	2 (0.7)	10 (3.6)
Overall	880	865 (98.3)	15 (1.7)	33 (3.8)

Table 2.83: Summary of posterior odds ratios for ACS-ITT-aspirin set.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Intermediate	1.09	(0.48, 2.48)	1.19 (0.53)	0.42
Low with aspirin	0.89	(0.38, 2.07)	0.97 (0.44)	0.61
Age ≥ 60	2.45	(1.22, 4.87)	2.60 (0.95)	0.01
Australia/New Zealand	0.41	(0.08, 1.58)	0.52 (0.40)	0.89

2.3.3.1.3 Therapeutic dose

- **Model:** logistic regression
- **Terms:** anticoagulation intervention, age group, region
- **Set:** ACS-ITT-therapeutic

Note: the reference region was switched to Nepal for this model due to small numbers in India.

Table 2.84: Summary of mortality to day 28 by treatment group, ACS-ITT-therapeutic.

n (%)	Patients	Known	Missing	Died by day 28
Low dose	79	75 (94.9)	4 (5.1)	3 (4.0)
Intermediate dose	65	63 (96.9)	2 (3.1)	1 (1.6)
Therapeutic dose	50	50 (100.0)	0 (0.0)	6 (12.0)
Overall	194	188 (96.9)	6 (3.1)	10 (5.3)

Table 2.85: Summary of posterior odds ratios for ACS-ITT-therapeutic. set.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Intermediate	0.66	(0.13, 3.11)	0.91 (0.86)	0.69
Therapeutic	2.64	(0.70, 10.68)	3.38 (2.75)	0.07
Age ≥ 60	2.80	(0.78, 11.41)	3.60 (3.05)	0.06
India	0.42	(0.08, 1.81)	0.55 (0.46)	0.87
Australia/New Zealand	0.28	(0.06, 1.02)	0.35 (0.26)	0.97

2.3.4 Days alive and free of hospital to day 28

This section reports on the analysis of the secondary outcome: days alive and free of hospital (DAFH) to day 28. For this outcome, participants who died within 28 days were coded to have 0 DAFH. The model is coded so that an odds ratio greater than 1 implies a benefit (increased odds of more days alive and free of hospital).

- **Model:** cumulative logistic (ordinal) regression assuming proportional odds
- **Terms:** anticoagulation intervention, antiviral intervention, aspirin eligibility, age group, region, site nested within region, and epoch.
- **Set:** ACS-ITT

Table 2.86 presents the number of participants where the outcome was observed by the allocated anticoagulation arm. The observed distribution of DAFH by arm is shown in Figure 2.43, Figure 2.44, and Figure 2.45. The model parameters (odds ratios) are summarised in Table 2.87 for the fixed-effect terms and in Figure 2.46 for the site and epoch specific terms.

Table 2.86: Summary of days alive and free of hospital to day 28 by treatment group, ACS-ITT.

Anticoagulation intervention	Patients	Known	Deaths	DAFH, Median (Q1, Q3)
Low-dose	610	596	19 (3%)	23 (21, 24)
Intermediate-dose	613	603	15 (2%)	23 (21, 24)
Low-dose with aspirin	283	280	10 (4%)	22 (20, 24)
Therapeutic-dose	50	50	6 (12%)	22 (19, 24)
Overall	1556	1529	50 (3%)	23 (21, 24)

Table 2.87: Summary of model parameters (fixed-effects odds-ratios) for days alive and free of hospital to day 28 outcome model fit to the ACS-ITT set.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR > 1)
Intermediate	1.14	(0.94, 1.39)	1.15 (0.12)	0.90
Low with aspirin	1.05	(0.80, 1.39)	1.06 (0.15)	0.65
Therapeutic	0.74	(0.41, 1.35)	0.77 (0.24)	0.16
Ineligible aspirin	1.08	(0.56, 2.05)	1.14 (0.39)	0.59
Age ≥ 60	0.58	(0.47, 0.71)	0.59 (0.06)	0.00
AU/NZ	0.75	(0.33, 1.73)	0.82 (0.37)	0.25
NP	0.68	(0.23, 2.62)	0.86 (0.72)	0.26




Figure 2.43: Observed overall distribution of days alive and free of hospital at day 28, ACS-ITT.




Figure 2.44: Observed distribution of days alive and free of hospital at day 28 by treatment group, ACS-ITT.




Figure 2.45: Observed cumulative distribution of days alive and free of hospital at day 28 by treatment group, ACS-ITT.




Figure 2.46: Posterior Summaries (point - median, block - 75% CrI, line - 95% CrI) of odds ratio for epoch and site effects on days alive and free of hospital to day 28 for the outcome model fit to the ACS-ITT set.

2.3.4.1 Sensitivity: Concurrent Enrolments

2.3.4.1.1 Intermediate dose

- **Model:** cumulative logistic (ordinal) regression assuming proportional odds
- **Terms:** anticoagulation intervention, age group, region
- **Set:** ACS-ITT-intermediate

Table 2.88: Summary of days alive and free of hospital to day 28 by treatment group, ACS-ITT-intermediate.

Anticoagulation intervention	Patients	Known	Deaths	DAFH, Median (Q1, Q3)
Low-dose	610	596	19 (3%)	23 (21, 24)
Intermediate-dose	613	603	15 (2%)	23 (21, 24)
Overall	1223	1199	34 (3%)	23 (21, 24)




Figure 2.47: Observed distribution of days alive and free of hospital at day 28 by treatment group, ACS-ITT-intermediate.

Table 2.89: Summary of days alive and free of hospital to day 28 by treatment group, ACS-ITT-intermediate.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR > 1)
Intermediate	1.17	(0.95, 1.42)	1.17 (0.12)	0.93
Age ≥ 60	0.51	(0.41, 0.64)	0.52 (0.06)	0.00
Australia/New Zealand	0.61	(0.43, 0.87)	0.62 (0.11)	0.00
Nepal	0.60	(0.40, 0.91)	0.61 (0.13)	0.01

2.3.4.1.2 Standard dose plus aspirin

- **Model:** cumulative logistic (ordinal) regression assuming proportional odds
- **Terms:** anticoagulation intervention, age group, region
- **Set:** ACS-ITT-aspirin

Table 2.90: Summary of days alive and free of hospital to day 28 by treatment group, ACS-ITT-aspirin.

Anticoagulation intervention	Patients	Known	Deaths	DAFH, Median (Q1, Q3)
Low-dose	299	291	11 (4%)	22 (20, 24)
Intermediate-dose	298	293	12 (4%)	22 (21, 24)
Low-dose with aspirin	283	280	10 (4%)	22 (20, 24)
Overall	880	864	33 (4%)	22 (20, 24)

Table 2.91: Summary of days alive and free of hospital to day 28 by treatment group, ACS-ITT-aspirin.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR > 1)
Intermediate	1.30	(0.98, 1.72)	1.32 (0.19)	0.97
Low with aspirin	1.12	(0.84, 1.49)	1.13 (0.17)	0.78
Age ≥ 60	0.57	(0.44, 0.74)	0.57 (0.08)	0.00
Australia/New Zealand	0.97	(0.60, 1.57)	1.00 (0.25)	0.45

2.3.4.1.3 Therapeutic dose

- **Model:** cumulative logistic (ordinal) regression assuming proportional odds
- **Terms:** anticoagulation intervention, age group, region




Figure 2.48: Observed distribution of days alive and free of hospital at day 28 by treatment group, ACS-ITT-aspirin.

- **Set:** ACS-ITT-therapeutic

Note: the reference region was switched to Nepal for this model due to small numbers in India.

Table 2.92: Summary of days alive and free of hospital to day 28 by treatment group, ACS-ITT-therapeutic

Anticoagulation intervention	Patients	Known	Deaths	DAFH, Median (Q1, Q3)
Low-dose	79	75	3 (4%)	22 (20, 24)
Intermediate-dose	65	63	1 (2%)	22 (20, 24)
Therapeutic-dose	50	50	6 (12%)	22 (19, 24)
Overall	194	188	10 (5%)	22 (19, 24)

Table 2.93: Summary of days alive and free of hospital to day 28 by treatment group, ACS-ITT-therapeutic

Parameter	Median	95% CrI	Mean (SD)	Pr(OR > 1)
Intermediate	1.17	(0.65, 2.11)	1.22 (0.38)	0.70
Therapeutic	0.85	(0.46, 1.58)	0.90 (0.29)	0.31
Age ≥ 60	0.44	(0.25, 0.75)	0.46 (0.13)	0.00
India	1.60	(0.74, 3.52)	1.73 (0.72)	0.88
Australia/New Zealand	1.30	(0.75, 2.25)	1.35 (0.39)	0.82




Figure 2.49: Observed distribution of days alive and free of hospital at day 28 by treatment group, ACS-ITT-therapeutic

2.3.5 Days alive and free of invasive or non-invasive ventilation to day 28

This section reports on the analysis of the secondary outcome: days alive and free invasive or non-invasive ventilation (DAFV) to day 28. For this outcome, participants who died within 28 days were coded to have 0 DAFV.

- **Model:** cumulative logistic (ordinal) regression assuming proportional odds
- **Terms:** anticoagulation intervention, antiviral intervention, aspirin eligibility, age group, region, site nested within region, and epoch.
- **Set:** ACS-ITT

Table 2.94 presents the number of participants where the outcome was observed by the allocated anticoagulation arm. The observed distribution of DAFV by arm is shown in Figure 2.50.

Table 2.94: Summary of days alive and free of ventilation to day 28 by treatment group.

Anticoagulation intervention	Patients	Known	Deaths	Any ventilation	DAFV, Median (Q1, Q3)
Low-dose	610	596	19 (3%)	34 (6%)	28 (28, 28)
Intermediate-dose	613	603	15 (2%)	23 (4%)	28 (28, 28)
Low-dose with aspirin	283	281	10 (4%)	18 (6%)	28 (28, 28)
Therapeutic-dose	50	50	6 (12%)	7 (14%)	28 (28, 28)
Overall	1556	1530	50 (3%)	82 (5%)	28 (28, 28)

Table 2.95: Summary of model parameters (fixed-effects odds-ratios) for days alive and free of ventilation to day 28 primary model fit to the ACS-ITT set.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR > 1)
Intermediate	1.40	(0.81, 2.45)	1.46 (0.42)	0.88
Low with aspirin	1.16	(0.62, 2.19)	1.22 (0.41)	0.68
Therapeutic	0.41	(0.15, 1.15)	0.47 (0.27)	0.05
Ineligible aspirin	0.29	(0.09, 1.08)	0.37 (0.28)	0.03
Age ≥ 60	0.50	(0.31, 0.83)	0.52 (0.13)	0.00
AU/NZ	1.10	(0.27, 4.92)	1.47 (1.28)	0.55
NP	0.56	(0.15, 2.32)	0.74 (0.68)	0.20




Figure 2.50: Observed distribution of days alive and free of ventilation at day 28 by treatment group.




Figure 2.51: Posterior Summaries (point - median, block - 75% CrI, line - 95% CrI) of odds ratio for epoch and site effects on days alive and free of ventilation to day 28 for the primary model fit to the ACS-ITT set.

2.3.5.1 Sensitivity: Concurrent Enrolments

2.3.5.1.1 Intermediate dose

- **Model:** cumulative logistic (ordinal) regression assuming proportional odds
- **Terms:** anticoagulation intervention, age group, region
- **Set:** ACS-ITT-intermediate

Table 2.96: Summary of days alive and free of ventilation to day 28 by treatment group, ACS-ITT-intermediate.

Anticoagulation intervention	Patients	Known	Deaths	Any ventilation	DAFV, Median (Q1, Q3)
Low-dose	610	596	19 (3%)	34 (6%)	28 (28, 28)
Intermediate-dose	613	603	15 (2%)	23 (4%)	28 (28, 28)
Overall	1223	1199	34 (3%)	57 (5%)	28 (28, 28)




Figure 2.52: Observed distribution of days alive and free of ventilation at day 28 by treatment group, ACS-ITT-intermediate.

Table 2.97: Summary of days alive and free of ventilation to day 28 by treatment group, ACS-ITT-intermediate.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR > 1)
Intermediate	1.51	(0.91, 2.59)	1.57 (0.43)	0.94
Age ≥ 60	0.43	(0.25, 0.74)	0.44 (0.13)	0.00
Australia/New Zealand	0.73	(0.36, 1.62)	0.80 (0.33)	0.21
Nepal	0.92	(0.40, 2.44)	1.05 (0.54)	0.43

2.3.5.1.2 Standard dose plus aspirin

- **Model:** cumulative logistic (ordinal) regression assuming proportional odds
- **Terms:** anticoagulation intervention, age group, region
- **Set:** ACS-ITT-aspirin

Table 2.98: Summary of days alive and free of ventilation to day 28 by treatment group, ACS-ITT-aspirin.

Anticoagulation intervention	Patients	Known	Deaths	Any ventilation	DAFV, Median (Q1, Q3)
Low-dose	299	291	11 (4%)	20 (7%)	28 (28, 28)
Intermediate-dose	298	293	12 (4%)	15 (5%)	28 (28, 28)
Low-dose with aspirin	283	281	10 (4%)	18 (6%)	28 (28, 28)
Overall	880	865	33 (4%)	53 (6%)	28 (28, 28)

Table 2.99: Summary of days alive and free of ventilation to day 28 by treatment group, ACS-ITT-aspirin.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR > 1)
Intermediate	1.32	(0.68, 2.61)	1.40 (0.50)	0.79
Low with aspirin	1.13	(0.60, 2.19)	1.20 (0.41)	0.65
Age ≥ 60	0.51	(0.29, 0.89)	0.53 (0.16)	0.01
Australia/New Zealand	3.15	(0.90, 14.44)	4.28 (3.96)	0.96

2.3.5.1.3 Therapeutic dose

- **Model:** cumulative logistic (ordinal) regression assuming proportional odds
- **Terms:** anticoagulation intervention, age group, region




Figure 2.53: Observed distribution of days alive and free of ventilation at day 28 by treatment group, ACS-ITT-aspirin.

- **Set:** ACS-ITT-therapeutic

Note: the reference region was switched to Nepal for this model due to small numbers in India.

Table 2.100: Summary of days alive and free of ventilation to day 28 by treatment group, ACS-ITT-therapeutic.

Anticoagulation intervention	Patients	Known	Deaths	Any ventilation	DAFV, Median (Q1, Q3)
Low-dose	79	75	3 (4%)	6 (8%)	28 (28, 28)
Intermediate-dose	65	63	1 (2%)	3 (5%)	28 (28, 28)
Therapeutic-dose	50	50	6 (12%)	7 (14%)	28 (28, 28)
Overall	194	188	10 (5%)	16 (8%)	28 (28, 28)

Table 2.101: Summary of days alive and free of ventilation to day 28 by treatment group, ACS-ITT-therapeutic.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR > 1)
Intermediate	1.46	(0.44, 5.22)	1.81 (1.32)	0.73
Therapeutic	0.57	(0.19, 1.71)	0.67 (0.41)	0.16
Age ≥ 60	0.58	(0.21, 1.61)	0.67 (0.37)	0.15
India	2.63	(0.67, 12.56)	3.64 (3.39)	0.91
Australia/New Zealand	1.13	(0.44, 3.04)	1.28 (0.70)	0.59




Figure 2.54: Observed distribution of days alive and free of ventilation at day 28 by treatment group, ACS-ITT-therapeutic.

2.3.6 Presence of patient reported shortness of breath at day 28

This section reports on the analysis of the secondary outcome: patient reported shortness of breath at day 28. For this outcome, participants who died within 28 days were coded to have a missing value, so this outcome reflects shortness of breath at day 28 amongst patients who survived to at least day 28. The model is coded so that an odds ratio less than 1 implies a benefit (reduction in odds of shortness of breath at day 28).

- **Model:** logistic regression
- **Terms:** anticoagulation intervention, antiviral intervention, aspirin eligibility, age group, region, site nested within region, and epoch.
- **Set:** ACS-ITT

Table 2.102 presents the number of participants where the outcome was observed by the allocated anticoagulation arm. The model parameters (odds ratios) are summarised in Table 2.103 for the fixed-effect terms and in Figure 2.55 for the site and epoch specific terms.

Table 2.102: Summary of patient reported shortness of breath at day 28 by treatment group.

n (%)	Patients	Known	Missing	Shortness of breath day 28
Low dose	610	577 (94.6)	33 (5.4)	115 (19.9)
Intermediate dose	613	584 (95.3)	29 (4.7)	110 (18.8)
Low dose with aspirin	283	271 (95.8)	12 (4.2)	59 (21.8)
Therapeutic dose	50	44 (88.0)	6 (12.0)	11 (25.0)
Overall	1556	1476 (94.9)	80 (5.1)	295 (20.0)

Table 2.103: Summary of model parameters (fixed-effects odds-ratios) for shortness of breath at day 28 primary model fit to the ACS-ITT set.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Intermediate	0.77	(0.55, 1.09)	0.79 (0.14)	0.93
Low with aspirin	1.19	(0.77, 1.84)	1.22 (0.28)	0.22
Therapeutic	0.93	(0.35, 2.30)	1.02 (0.50)	0.57
Ineligible aspirin	1.19	(0.40, 3.31)	1.36 (0.77)	0.38
Age ≥ 60	2.09	(1.48, 2.94)	2.12 (0.37)	0.00
Australia/New Zealand	2.32	(0.59, 8.49)	2.89 (2.20)	0.11
Nepal	0.52	(0.13, 2.52)	0.72 (0.71)	0.81




Figure 2.55: Posterior Summaries (point - median, block - 75% CrI, line - 95% CrI) of odds ratio for epoch and site effects on day 28 shortness of breath for the primary model fit to the ACS-ITT set.

2.3.6.1 Sensitivity: Concurrent Enrolments

2.3.6.1.1 Intermediate dose

- **Model:** logistic regression
- **Terms:** anticoagulation intervention, age group, region
- **Set:** ACS-ITT-intermediate

Table 2.104: Summary of shortness of breath at day 28 by treatment group, ACS-ITT-intermediate.

n (%)	Patients	Known	Missing	Shortness of breath day 28
Low dose	610	577 (94.6)	33 (5.4)	115 (19.9)
Intermediate dose	613	584 (95.3)	29 (4.7)	110 (18.8)
Overall	1223	1161 (94.9)	62 (5.1)	225 (19.4)

Table 2.105: Summary of posterior odds ratios, ACS-ITT-intermediate.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Intermediate	0.91	(0.67, 1.23)	0.92 (0.14)	0.74
Age ≥ 60	1.64	(1.19, 2.24)	1.66 (0.27)	0.00
Australia/New Zealand	3.91	(2.62, 5.82)	4.00 (0.82)	0.00
Nepal	0.47	(0.22, 0.92)	0.50 (0.18)	0.99

2.3.6.1.2 Standard dose plus aspirin

- **Model:** logistic regression
- **Terms:** anticoagulation intervention, age group, region
- **Set:** ACS-ITT-aspirin

Table 2.106: Summary of shortness of breath at day 28 by treatment group, ACS-ITT-aspirin.

n (%)	Patients	Known	Missing	Shortness of breath day 28
Low dose	299	280 (93.6)	19 (6.4)	55 (19.6)
Intermediate dose	298	280 (94.0)	18 (6.0)	52 (18.6)
Low dose with aspirin	283	271 (95.8)	12 (4.2)	59 (21.8)
Overall	880	831 (94.4)	49 (5.6)	166 (20.0)

Table 2.107: Summary of posterior odds ratios, ACS-ITT-aspirin.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Intermediate	0.96	(0.64, 1.46)	0.99 (0.21)	0.57
Low with aspirin	1.17	(0.78, 1.77)	1.20 (0.26)	0.22
Age ≥ 60	1.54	(1.05, 2.23)	1.56 (0.30)	0.01
Australia/New Zealand	2.17	(1.17, 3.91)	2.26 (0.70)	0.01

2.3.6.1.3 Therapeutic dose

- **Model:** logistic regression
- **Terms:** anticoagulation intervention, age group, region
- **Set:** ACS-ITT-therapeutic

Note: the reference region was switched to Nepal for this model due to small numbers in India.

Table 2.108: Summary of shortness of breath at day 28 by treatment group, ACS-ITT-therapeutic.

n (%)	Patients	Known	Missing	Shortness of breath day 28
Low dose	79	72 (91.1)	7 (8.9)	18 (25.0)
Intermediate dose	65	61 (93.8)	4 (6.2)	13 (21.3)
Therapeutic dose	50	44 (88.0)	6 (12.0)	11 (25.0)
Overall	194	177 (91.2)	17 (8.8)	42 (23.7)

Table 2.109: Summary of posterior odds ratios, ACS-ITT-therapeutic.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Intermediate	0.46	(0.18, 1.13)	0.51 (0.25)	0.95
Therapeutic	0.66	(0.25, 1.68)	0.74 (0.38)	0.80
Age ≥ 60	1.89	(0.84, 4.34)	2.07 (0.93)	0.06
India	1.25	(0.36, 4.03)	1.49 (0.96)	0.36
Australia/New Zealand	12.28	(5.66, 28.30)	13.51 (5.93)	0.00

2.3.7 Modified Medical Research Council (mMRC) breathlessness scale at day 28

The mMRC scale was only asked of participants who responded “yes” to the question of new or worsening breathlessness since COVID. Therefore, the distribution of this outcome scale is conditional on the patient responding that they were experiencing new or worse breathlessness since having COVID. In the following tables “Not asked” refers to participants who responded “no” to the question of breathlessness.

Table 2.110: mMRC breathlessness scale by anticoagulation intervention (day 28).

mMRC breathlessness scale (day 28)	Low	Intermediate	Low with aspirin	Therapeutic	Overall
Only breathless with strenuous exercise	40 (7)	50 (8)	26 (9)	2 (4)	118 (8)
Short of breath up a slight hill	47 (8)	39 (6)	16 (6)	4 (8)	106 (7)
Walks slower than most people of the same age	12 (2)	11 (2)	15 (5)	3 (6)	41 (3)
Stops for breath after walking about 100 metres	14 (2)	8 (1)	1 (0)	2 (4)	25 (2)
Too breathless to leave the house	2 (0)	2 (0)	1 (0)	0 (0)	5 (0)
Not asked	462 (76)	474 (77)	212 (75)	33 (66)	1181 (76)
(Missing)	33 (5)	29 (5)	12 (4)	6 (12)	80 (5)

Table 2.111: Summary of model parameters (fixed-effects odds-ratios) for the mMRC scale at day 28 primary model fit to the ACS-ITT set.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Intermediate	0.71	(0.42, 1.19)	0.73 (0.20)	0.91
Low with aspirin	1.09	(0.57, 2.11)	1.16 (0.40)	0.40
Therapeutic	0.73	(0.24, 2.25)	0.86 (0.54)	0.71
Ineligible aspirin	1.02	(0.24, 4.02)	1.30 (1.06)	0.49
Age ≥ 60	1.47	(0.92, 2.39)	1.52 (0.38)	0.05
Australia/New Zealand	2.65	(0.72, 9.65)	3.30 (2.44)	0.07
Nepal	1.36	(0.31, 5.39)	1.73 (1.39)	0.33




Figure 2.56: Posterior Summaries (point - median, block - 75% CrI, line - 95% CrI) of odds ratio for epoch and site effects on the mMRC scale at day 28 for the primary model fit to the ACS-ITT set.

2.3.8 Quality of life as measured by EQ-5D-5L questionnaire at day 28

The EQ-5D-5L responses are described.

Table 2.112: Prevalance of 10 most frequent, and worst, reported EQ-5D-5L profiles by treatment (day 28).

Health state	Frequency		Cumulative	
	n	%	n	%
Low				
11111	279	48.4	279	48.4
11121	36	6.2	315	54.7
11221	22	3.8	337	58.5
22211	18	3.1	355	61.6
11112	17	3	372	64.6
21111	16	2.8	388	67.4
11211	15	2.6	403	70
21121	15	2.6	418	72.6
21221	14	2.4	432	75
21211	13	2.3	445	77.3
...				
55533	1	0.2	576	100
Intermediate				
11111	304	52.1	304	52.1
11121	47	8	351	60.1
11221	24	4.1	375	64.2
22211	20	3.4	395	67.6
21121	17	2.9	412	70.5
21111	11	1.9	423	72.4
21211	11	1.9	434	74.3
11112	9	1.5	443	75.9
11211	9	1.5	452	77.4
11212	9	1.5	461	78.9
...				
55555	1	0.2	584	100
Low with aspirin				
11111	126	46.5	126	46.5
11121	27	10	153	56.5
11221	13	4.8	166	61.3
21111	11	4.1	177	65.3
22211	11	4.1	188	69.4
21121	9	3.3	197	72.7

11112	8	3	205	75.6
22221	5	1.8	210	77.5
11211	4	1.5	214	79
21221	4	1.5	218	80.4
...				
55555	1	0.4	271	100
Therapeutic				
11111	24	54.5	24	54.5
21111	3	6.8	27	61.4
22211	2	4.5	29	65.9
22232	2	4.5	31	70.5
11112	1	2.3	32	72.7
11121	1	2.3	33	75
11211	1	2.3	34	77.3
11213	1	2.3	35	79.5
11221	1	2.3	36	81.8
21213	1	2.3	37	84.1
...				
32223	1	2.3	44	100

Table 2.113: Distribution of responses on the EQ-5D-5L (day 28).

EQ-5D-5L	Low	Intermediate	Low with aspirin	Therapeutic	Overall
Mobility					
1	413 (56)	438 (60)	194 (56)	29 (49)	1074 (57)
2	130 (18)	124 (17)	63 (18)	11 (19)	328 (17)
3	27 (4)	16 (2)	8 (2)	4 (7)	55 (3)
4	4 (1)	5 (1)	5 (1)	0 (0)	14 (1)
5	2 (0)	1 (0)	1 (0)	0 (0)	4 (0)
Any mobility problem	163 (22)	146 (20)	77 (22)	15 (25)	401 (21)
Self care					
1	482 (72)	493 (73)	223 (70)	38 (76)	1236 (72)
2	79 (12)	79 (12)	39 (12)	6 (12)	203 (12)
3	10 (1)	7 (1)	7 (2)	0 (0)	24 (1)
4	2 (0)	3 (0)	0 (0)	0 (0)	5 (0)
5	3 (0)	2 (0)	2 (1)	0 (0)	7 (0)
Any self care problem	94 (14)	91 (13)	48 (15)	6 (12)	239 (14)
Usual activities					
1	396 (52)	426 (57)	192 (55)	29 (49)	1043 (55)
2	150 (20)	135 (18)	64 (18)	11 (19)	360 (19)
3	25 (3)	17 (2)	12 (3)	3 (5)	57 (3)
4	2 (0)	4 (1)	0 (0)	1 (2)	7 (0)

5	3 (0)	2 (0)	3 (1)	0 (0)	8 (0)
Any usual activities problem	180 (24)	158 (21)	79 (23)	15 (25)	432 (23)
Pain/discomfort					
1	394 (52)	396 (51)	174 (47)	33 (60)	997 (51)
2	139 (18)	154 (20)	82 (22)	5 (9)	380 (19)
3	38 (5)	28 (4)	9 (2)	6 (11)	81 (4)
4	4 (1)	5 (1)	5 (1)	0 (0)	14 (1)
5	1 (0)	1 (0)	1 (0)	0 (0)	3 (0)
Any pain/discomfort problem	182 (24)	188 (24)	97 (26)	11 (20)	478 (24)
Anxiety/depression					
1	475 (70)	495 (74)	230 (74)	32 (57)	1232 (72)
2	80 (12)	73 (11)	34 (11)	7 (12)	194 (11)
3	15 (2)	10 (1)	3 (1)	4 (7)	32 (2)
4	6 (1)	5 (1)	3 (1)	1 (2)	15 (1)
5	0 (0)	1 (0)	1 (0)	0 (0)	2 (0)
Any anxiety/depression problem	101 (15)	89 (13)	41 (13)	12 (21)	243 (14)

Table 2.114: Descriptive summary of EQ-5D VAS (day 28).

	Low	Intermediate	Low with aspirin	Therapeutic
n	610	613	283	50
Mean	85.1	85.8	85.2	86.1
SD	11.8	11.4	11.1	13.7
Median	90	90	90	90
Mode	90	90	90	90
Min	9	10	30	50
Max	100	100	100	100
Missing, n (%)	36 (5.9)	33 (5.38)	12 (4.24)	7 (14)

2.4 Domain Specific Outcomes

The anticoagulation domain-specific outcomes are reported in Table 2.115. The number of thrombotic and bleeding events were low across all interventions and overall.

Table 2.115: Descriptive summary of anticoagulation-specific outcomes (thrombotic and bleeding events).

Outcome, n (%)	Low dose (n = 610)	Intermediate dose (n = 613)	Low dose with aspirin (n = 283)	Therapeutic dose (n = 50)	Overall (n = 1556)
Mortality					
Died by day 28	19 (3)	15 (2)	10 (4)	6 (12)	50 (3)
Unknown	14 (2)	10 (2)	2 (1)	0 (0)	26 (2)
Thrombotic events					
Unknown	18 (3)	14 (2)	5 (2)	2 (4)	39 (3)
Deep vein thrombosis	1/592 (0)	0/599 (0)	0/278 (0)	0/48 (0)	1/1517 (0)
Pulmonary embolus	0/592 (0)	1/599 (0)	1/278 (0)	0/48 (0)	2/1517 (0)
Acute myocardial infarction	1/592 (0)	1/599 (0)	0/278 (0)	0/48 (0)	2/1517 (0)
Ischemic cerebrovascular event	0/592 (0)	0/599 (0)	0/278 (0)	0/48 (0)	0/1517 (0)
Other confirmed thrombotic event	1/592 (0)	0/599 (0)	0/278 (0)	0/48 (0)	1/1517 (0)
Any thrombotic event	3/592 (1)	2/599 (0)	1/278 (0)	0/48 (0)	6/1517 (0)
Any thrombotic event or death	21/592 (4)	17/600 (3)	11/279 (4)	6/49 (12)	55/1520 (4)
Bleeding					
Unknown	15 (2)	13 (2)	4 (1)	2 (4)	34 (2)
Major bleeding (as defined by ISTH)	1 (0)	2 (0)	3 (1)	0 (0)	6 (0)
Clinically relevant non-major bleeding	2 (0)	2 (0)	2 (1)	2 (4)	8 (1)
Any clinically relevant bleeding	3 (1)	4 (1)	3 (1)	2 (4)	12 (1)
Heparin-induced thrombocytopenia	0 (0)	1 (0)	0 (0)	0 (0)	1 (0)

The SAP described a formal analysis of the two composite outcomes: any thrombotic event (or death), and any clinical relevant bleeding. Due to the small number of bleeding events this analysis was not undertaken. Similarly, for any thrombotic event or death, due to the majority of the events being due to death, the results were expected to be similar to those for all-cause mortality to day 28. Despite this, the analysis *was* performed for any thrombotic event or death and the results reported below.

2.4.1 Any thrombotic event (or death) to day 28

Table 2.116: Summary of model parameters (fixed-effects odds-ratios) for any thrombotic event or death to day 28 for primary model fit to the ACS-ITT set.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Intermediate	0.85	(0.44, 1.65)	0.90 (0.31)	0.68
Low with aspirin	0.87	(0.39, 1.90)	0.94 (0.39)	0.64
Therapeutic	2.47	(0.82, 7.47)	2.91 (1.84)	0.06
Ineligible aspirin	4.66	(1.18, 15.91)	5.65 (3.94)	0.01
Age ≥ 60	2.06	(1.14, 3.75)	2.15 (0.66)	0.01
Australia/NZ	0.96	(0.22, 3.94)	1.25 (1.03)	0.52
Nepal	2.51	(0.56, 9.18)	3.11 (2.41)	0.10




Figure 2.57: Posterior Summaries (point - median, block - 75% CrI, line - 95% CrI) of odds ratio for epoch and site effects for any thrombotic event or death to day 28 for the primary model fit to the ACS-ITT set.

3 Appendix

3.1 Outcomes by Model Covariates (ACS-ITT)

3.1.1 Primary Outcome by Model Covariates (ACS-ITT)




Figure 3.1: Proportion of participants satisfying primary outcome criteria by age at randomisation, ACS-ITT. Vertical dashed line indicates the pre-specified cut-point of 60 years of age.




Figure 3.2: Proportion of participants satisfying primary outcome criteria by country of randomisation, ACS-ITT.




Figure 3.3: Proportion of participants satisfying primary outcome criteria by country and site of randomisation, ACS-ITT.




Figure 3.4: Proportion of participants satisfying primary outcome criteria by calendar time (month) of randomisation, ACS-ITT.




Figure 3.5: Proportion of participants satisfying primary outcome criteria by days since first symptoms at randomisation, ACS-ITT. Vertical dashed line indicates the pre-specified cut-point of 7 days.

3.1.2 Time to recovery to day 28 by model covariates (ACS-ITT)




Figure 3.6: Time to clinical recovery to day 28 by age group at randomisation, ACS-ITT.




Figure 3.7: Time to clinical recovery to day 28 by country of randomisation, ACS-ITT.




Figure 3.8: Time to clinical recovery to day 28 by country and site of randomisation, ACS-ITT.




Figure 3.9: Time to clinical recovery to day 28 by calendar time (month) of randomisation, ACS-ITT.

3.1.3 WHO outcome scale at day 28 by model covariates (ACS-ITT)




Figure 3.10: Distribution of WHO outcome scale day 28 by age at randomisation, ACS-ITT. Vertical dashed line indicates the pre-specified cut-point of 60 years of age.




Figure 3.11: Distribution of WHO scale at day 28 by country of randomisation, ACS-ITT.




Figure 3.12: Distribution of WHO scale at day 28 by country and site of randomisation, ACS-ITT.




Figure 3.13: Distribution of WHO scale at day 28 by calendar time (month) of randomisation, ACS-ITT.

3.1.4 Mortality to day 28 by Model Covariates (ACS-ITT)




Figure 3.14: Proportion of participants who died by day 28 by age at randomisation, ACS-ITT. Vertical dashed line indicates the pre-specified cut-point of 60 years of age.




Figure 3.15: Proportion of participants who died by day 28 by country of randomisation, ACS-ITT.




Figure 3.16: Proportion of participants who died by day 28 by country and site of randomisation, ACS-ITT.




Figure 3.17: Proportion of participants who died by day 28 by calendar time (month) of randomisation, ACS-ITT.

3.1.5 Days alive and free of hospital to day 28 by Model Covariates (ACS-ITT)




Figure 3.18: Distribution of days alive and free of hospital to day 28 by age groups, ACS-ITT.




Figure 3.19: Distribution of days alive and free of hospital to day 28 by country of randomisation, ACS-ITT.




Figure 3.20: Distribution of days alive and free of hospital to day 28 by country and site of randomisation, ACS-ITT.




Figure 3.21: Distribution of days alive and free of hospital to day 28 by calendar time (month) of randomisation, ACS-ITT.

3.1.6 Days alive and free of ventilation to day 28 by Model Covariates (ACS-ITT)




Figure 3.22: Distribution of days alive and free of ventilation to day 28 by age groups, ACS-ITT.




Figure 3.23: Distribution of days alive and free of ventilation to day 28 by country of randomisation, ACS-ITT.




Figure 3.24: Distribution of days alive and free of ventilation to day 28 by country and site of randomisation, ACS-ITT.




Figure 3.25: Distribution of days alive and free of ventilation to day 28 by calendar time (month) of randomisation, ACS-ITT.

3.1.7 Presence of patient reported shortness of breath at day 28 by model covariates (ACS-ITT)




Figure 3.26: Proportion with patient reported shortness of breath at day 28 by age groups.




Figure 3.27: Proportion with patient reported shortness of breath at day 28 by country of randomisation.




Figure 3.28: Proportion with patient reported shortness of breath at day 28 by country and site of randomisation.




Figure 3.29: Proportion with patient reported shortness of breath at day 28 by calendar time (month) of randomisation.

3.2 Primary Model Posterior Predictive Summaries

3.2.1 Primary Outcome




Figure 3.30: Posterior predictive distribution for primary outcome by model covariates for primary model using ACS-ITT. Red diamond indicates observed proportions.

3.2.2 WHO outcome scale dat day 28




Figure 3.31: Posterior predictive distribution for WHO scale by model covariates for primary model using ACS-ITT. Red diamond indicates observed proportions.

3.2.3 Mortality to day 28




Figure 3.32: Posterior predictive distribution for mortality to day 28 by model covariates for primary model using ACS-ITT. Red diamond indicates observed proportions.

3.2.4 Days alive and free of hospital to day 28




Figure 3.33: Posterior predictive distribution for days alive and free of hospital to day 28 by model covariates (intervention, country, and epoch) for primary model using ACS-ITT. Red diamond indicates observed proportions.




Figure 3.34: Posterior predictive distribution for days alive and free of hospital to day 28 by model covariates (site) for primary model using ACS-ITT. Red diamond indicates observed proportions.

3.2.5 Days alive and free of ventilation to day 28




Figure 3.35: Posterior predictive distribution for days alive and free of ventilation to day 28 by model covariates (intervention, country, and epoch) for primary model using ACS-ITT. Red diamond indicates observed proportions.




Figure 3.36: Posterior predictive distribution for days alive and free of ventilation to day 28 by model covariates (site) for primary model using ACS-ITT. Red diamond indicates observed proportions.

3.2.6 Presence of patient reported shortness of breath at day 28




Figure 3.37: Posterior predictive distribution for shortness of breath at day 28 by model covariates for primary model using ACS-ITT. Red diamond indicates observed proportions.

3.2.7 mMRC Breathlessness Scale




Figure 3.38: Posterior predictive distribution for mMRC scale by model covariates for primary model using ACS-ITT. Red diamond indicates observed proportions.

3.3 Baseline Characteristics for Concurrent Sets

3.3.1 Demographics

Table 3.1: Baseline demographics for participants included in ACS-ITT-aspirin.

Variable	Anticoagulation			Overall (n = 880)
	Low-dose (n = 299)	Intermediate-dose (n = 298)	Low-dose with aspirin (n = 283)	
Age (years), Median (IQR)	48 (37, 60)	47 (37, 60)	50 (38, 62)	48 (37, 61)
Country				
India, n (%)	274 (92)	279 (94)	275 (97)	828 (94)
Australia, n (%)	22 (7)	17 (6)	7 (2)	46 (5)
Nepal, n (%)	0 (0)	0 (0)	0 (0)	0 (0)
New Zealand, n (%)	3 (1)	2 (1)	1 (0)	6 (1)
Sex				
Male, n (%)	175 (59)	194 (65)	157 (55)	526 (60)
Female, n (%)	124 (41)	104 (35)	126 (45)	354 (40)
Weight (kg)				
Median, (IQR)	68 (62, 75)	69 (62, 75)	68 (62, 76)	68 (62, 75)
Missing, n (%)	0 (0)	0 (0)	0 (0)	0 (0)
Vaccinated¹				
Yes, n (%)	46 (15)	48 (16)	42 (15)	136 (15)
Missing, n (%)	31 (10)	22 (7)	29 (10)	82 (9)
Ethnicity				
Indian, n (%)	274 (92)	280 (94)	275 (97)	829 (94)
European, n (%)	4 (1)	2 (1)	4 (1)	10 (1)
Asian, n (%)	3 (1)	3 (1)	1 (0)	7 (1)
Pacific Islander, n (%)	4 (1)	3 (1)	2 (1)	9 (1)
Middle Eastern, n (%)	9 (3)	5 (2)	0 (0)	14 (2)
Maori, n (%)	1 (0)	2 (1)	0 (0)	3 (0)
African, n (%)	1 (0)	0 (0)	1 (0)	2 (0)
Aboriginal, n (%)	0 (0)	0 (0)	0 (0)	0 (0)
Latin American, n (%)	0 (0)	0 (0)	0 (0)	0 (0)
Other, n (%)	1 (0)	0 (0)	0 (0)	1 (0)
Unknown, n (%)	4 (1)	3 (1)	0 (0)	7 (1)
Smoking				
Current, n (%)	5 (2)	7 (2)	3 (1)	15 (2)
Former, n (%)	22 (7)	12 (4)	15 (5)	49 (6)
Never, n (%)	272 (91)	279 (94)	265 (94)	816 (93)
Missing, n (%)	0 (0)	0 (0)	0 (0)	0 (0)

¹ Site LUD did not have ethics approval for collection of vaccination status.

Table 3.2: Baseline demographics for participants included in ACS-ITT-therapeutic

Variable	Anticoagulation			Overall
	Low-dose (n = 79)	Intermediate-dose (n = 65)	Therapeutic-dose (n = 50)	
Age (years), Median (IQR)	54 (39, 66)	52 (37, 70)	58 (46, 69)	54 (39, 69)
Country				
India, n (%)	6 (8)	8 (12)	4 (8)	18 (9)
Australia, n (%)	11 (14)	22 (34)	11 (22)	44 (23)
Nepal, n (%)	56 (71)	31 (48)	31 (62)	118 (61)
New Zealand, n (%)	6 (8)	4 (6)	4 (8)	14 (7)
Sex				
Male, n (%)	38 (48)	35 (54)	25 (50)	98 (51)
Female, n (%)	41 (52)	30 (46)	25 (50)	96 (49)
Weight (kg)				
Median, (IQR)	68 (60, 86)	74 (63, 85)	66 (57, 80)	69 (60, 85)
Missing, n (%)	0 (0)	0 (0)	0 (0)	0 (0)
Vaccinated¹				
Yes, n (%)	45 (57)	43 (66)	27 (54)	115 (59)
Missing, n (%)	0 (0)	0 (0)	0 (0)	0 (0)
Ethnicity				
Indian, n (%)	7 (9)	9 (14)	4 (8)	20 (10)
European, n (%)	9 (11)	11 (17)	4 (8)	24 (12)
Asian, n (%)	16 (20)	9 (14)	10 (20)	35 (18)
Pacific Islander, n (%)	5 (6)	5 (8)	3 (6)	13 (7)
Middle Eastern, n (%)	0 (0)	1 (2)	0 (0)	1 (1)
Maori, n (%)	1 (1)	1 (2)	3 (6)	5 (3)
African, n (%)	0 (0)	0 (0)	0 (0)	0 (0)
Aboriginal, n (%)	0 (0)	0 (0)	1 (2)	1 (1)
Latin American, n (%)	0 (0)	1 (2)	0 (0)	1 (1)
Other, n (%)	41 (52)	26 (40)	23 (46)	90 (46)
Unknown, n (%)	2 (3)	2 (3)	3 (6)	7 (4)
Smoking				
Current, n (%)	8 (10)	8 (12)	5 (10)	21 (11)
Former, n (%)	30 (38)	15 (23)	14 (28)	59 (30)
Never, n (%)	41 (52)	42 (65)	31 (62)	114 (59)
Missing, n (%)	0 (0)	0 (0)	0 (0)	0 (0)

¹ Site LUD did not have ethics approval for collection of vaccination status.

Table 3.3: Baseline demographics for participants who were not part of ACS-ITT-aspirin or ACS-ITT-therapeutic.

Variable	Anticoagulation		Overall (n = 482)
	Low-dose	Intermediate-dose	
	(n = 232)	(n = 250)	
Age (years), Median (IQR)	47 (36, 58)	48 (36, 62)	47 (36, 60)
Country			
India, n (%)	213 (92)	229 (92)	442 (92)
Australia, n (%)	16 (7)	20 (8)	36 (7)
Nepal, n (%)	0 (0)	0 (0)	0 (0)
New Zealand, n (%)	3 (1)	1 (0)	4 (1)
Sex			
Male, n (%)	141 (61)	158 (63)	299 (62)
Female, n (%)	91 (39)	92 (37)	183 (38)
Weight (kg)			
Median, (IQR)	69 (62, 76)	70 (62, 76)	69 (62, 76)
Missing, n (%)	0 (0)	0 (0)	0 (0)
Vaccinated¹			
Yes, n (%)	100 (43)	129 (52)	229 (48)
Missing, n (%)	1 (0)	0 (0)	1 (0)
Ethnicity			
Indian, n (%)	213 (92)	229 (92)	442 (92)
European, n (%)	8 (3)	5 (2)	13 (3)
Asian, n (%)	1 (0)	0 (0)	1 (0)
Pacific Islander, n (%)	4 (2)	4 (2)	8 (2)
Middle Eastern, n (%)	2 (1)	5 (2)	7 (1)
Maori, n (%)	1 (0)	1 (0)	2 (0)
African, n (%)	0 (0)	0 (0)	0 (0)
Aboriginal, n (%)	0 (0)	1 (0)	1 (0)
Latin American, n (%)	0 (0)	0 (0)	0 (0)
Other, n (%)	3 (1)	2 (1)	5 (1)
Unknown, n (%)	2 (1)	4 (2)	6 (1)
Smoking			
Current, n (%)	4 (2)	6 (2)	10 (2)
Former, n (%)	22 (9)	26 (10)	48 (10)
Never, n (%)	206 (89)	218 (87)	424 (88)
Missing, n (%)	0 (0)	0 (0)	0 (0)

¹ Site LUD did not have ethics approval for collection of vaccination status.

3.3.2 Co-morbidities

Table 3.4: Baseline comorbidities for participants included in ACS-ITT-aspirin.

Comorbidity	Anticoagulation			Overall (n = 880)
	Low-dose (n = 299)	Intermediate-dose (n = 298)	Low-dose with aspirin (n = 283)	
None, n (%)	183 (61)	198 (66)	166 (59)	547 (62)
Diabetes, n (%)	74 (25)	63 (21)	78 (28)	215 (24)
Hypertension, n (%)	67 (22)	59 (20)	68 (24)	194 (22)
Asthma, n (%)	11 (4)	6 (2)	6 (2)	23 (3)
Obesity, n (%)	4 (1)	7 (2)	3 (1)	14 (2)
Chronic lung disease, n (%)	1 (0)	3 (1)	1 (0)	5 (1)
Chronic cardiac disease, n (%)	2 (1)	1 (0)	1 (0)	4 (0)
Obstructive sleep apnoea, n (%)	1 (0)	1 (0)	2 (1)	4 (0)
Chronic kidney disease, n (%)	0 (0)	1 (0)	1 (0)	2 (0)
Malignant neoplasm, n (%)	1 (0)	1 (0)	0 (0)	2 (0)
HIV infection, n (%)	1 (0)	0 (0)	0 (0)	1 (0)
Dialysis, n (%)	0 (0)	0 (0)	0 (0)	0 (0)
Moderate or severe liver disease, n (%)	0 (0)	0 (0)	0 (0)	0 (0)
Dementia, n (%)	0 (0)	0 (0)	0 (0)	0 (0)
Iatrogenic immunosuppression, n (%)	0 (0)	0 (0)	0 (0)	0 (0)
Missing, n (%)	0 (0)	0 (0)	0 (0)	0 (0)

Table 3.5: Baseline comorbidities for participants included in ACS-ITT-therapeutic

Comorbidity	Anticoagulation			Overall (n = 194)
	Low-dose (n = 79)	Intermediate-dose (n = 65)	Therapeutic-dose (n = 50)	
None, n (%)	37 (47)	28 (43)	19 (38)	84 (43)
Hypertension, n (%)	23 (29)	17 (26)	14 (28)	54 (28)
Diabetes, n (%)	12 (15)	16 (25)	11 (22)	39 (20)
Chronic lung disease, n (%)	12 (15)	6 (9)	7 (14)	25 (13)
Obesity, n (%)	11 (14)	8 (12)	5 (10)	24 (12)
Asthma, n (%)	6 (8)	6 (9)	4 (8)	16 (8)
Chronic cardiac disease, n (%)	3 (4)	4 (6)	2 (4)	9 (5)
Iatrogenic immunosuppression, n (%)	1 (1)	4 (6)	0 (0)	5 (3)
Obstructive sleep apnoea, n (%)	1 (1)	1 (2)	0 (0)	2 (1)
Chronic kidney disease, n (%)	0 (0)	2 (3)	0 (0)	2 (1)
Moderate or severe liver disease, n (%)	1 (1)	1 (2)	0 (0)	2 (1)
Malignant neoplasm, n (%)	0 (0)	1 (2)	1 (2)	2 (1)
Dialysis, n (%)	0 (0)	0 (0)	0 (0)	0 (0)
Dementia, n (%)	0 (0)	0 (0)	0 (0)	0 (0)
HIV infection, n (%)	0 (0)	0 (0)	0 (0)	0 (0)
Missing, n (%)	0 (0)	0 (0)	0 (0)	0 (0)

Table 3.6: Baseline comorbidities for participants who were not part of ACS-ITT-aspirin or ACS-ITT-therapeutic.

Comorbidity	Anticoagulation		Overall (n = 482)
	Low-dose (n = 232)	Intermediate-dose (n = 250)	
None, n (%)	144 (62)	152 (61)	296 (61)
Hypertension, n (%)	57 (25)	64 (26)	121 (25)
Diabetes, n (%)	54 (23)	60 (24)	114 (24)
Chronic cardiac disease, n (%)	6 (3)	10 (4)	16 (3)
Obesity, n (%)	8 (3)	7 (3)	15 (3)
Chronic lung disease, n (%)	3 (1)	4 (2)	7 (1)
Asthma, n (%)	2 (1)	4 (2)	6 (1)
Chronic kidney disease, n (%)	0 (0)	2 (1)	2 (0)
Iatrogenic immunosuppression, n (%)	0 (0)	2 (1)	2 (0)
Obstructive sleep apnoea, n (%)	1 (0)	0 (0)	1 (0)
Dialysis, n (%)	0 (0)	1 (0)	1 (0)
Moderate or severe liver disease, n (%)	1 (0)	0 (0)	1 (0)
Dementia, n (%)	0 (0)	0 (0)	0 (0)
Malignant neoplasm, n (%)	0 (0)	0 (0)	0 (0)
HIV infection, n (%)	0 (0)	0 (0)	0 (0)
Missing, n (%)	0 (0)	0 (0)	0 (0)

3.3.3 Prognostics

Table 3.7: Baseline prognostics for participants included in ACS-ITT-aspirin.

Variable	Anticoagulation			Overall (n = 880)
	Low dose (n = 299)	Intermediate dose (n = 298)	Low dose with aspirin (n = 283)	
Was the patient on room air for any of the preceding 24 hours?				
Yes, n (%)	244 (82)	232 (78)	224 (79)	700 (80)
Missing, n (%)	8 (3)	8 (3)	8 (3)	24 (3)
Was the patient's GCS < 15?				
Yes, n (%)	4 (1)	3 (1)	6 (2)	13 (1)
Missing, n (%)	75 (25)	75 (25)	60 (21)	210 (24)
Peripheral oxygen saturation (SpO2) on room air (Lowest)				
Median (IQR)	96 (94, 97)	96 (94, 98)	96 (94, 97)	96 (94, 97)
Missing, n (%)	55 (18)	66 (22)	59 (21)	180 (20)
Highest respiratory rate (breaths/minute)				
Median (IQR)	22 (20, 25)	22 (20, 26)	22 (20, 26)	22 (20, 26)
Missing, n (%)	0 (0)	0 (0)	0 (0)	0 (0)
Highest recorded Urea in the last 24 hours (mmol/L)				
Median (IQR)	4 (3, 5)	5 (4, 6)	4 (3, 6)	4 (3, 6)
Missing, n (%)	17 (6)	23 (8)	16 (6)	56 (6)
Highest recorded CRP in the last 24 hours (mg/L)				
Median (IQR)	75 (38, 200)	84 (36, 224)	77 (44, 223)	78 (40, 208)
Missing, n (%)	15 (5)	17 (6)	18 (6)	50 (6)
APTT¹				
Median (IQR)	32 (28, 36)	33 (29, 37)	32 (28, 37)	32 (29, 36)
Missing, n (%)	186 (62)	205 (69)	195 (69)	586 (67)
INR¹				
Mean (SD)	1.15 (0.27)	1.21 (0.63)	1.32 (1.34)	1.22 (0.85)
Missing, n (%)	41 (14)	47 (16)	47 (17)	135 (15)
Fibrinogen¹ (g/L)				
Mean (SD)	4.17 (1.91)	4.77 (1.40)	4.75 (1.40)	4.61 (1.55)
Missing, n (%)	277 (93)	273 (92)	243 (86)	793 (90)
Prothrombin time¹ (sec)				
Median (IQR)	14 (13, 16)	14 (13, 16)	15 (13, 16)	14 (13, 16)
Missing, n (%)	119 (40)	119 (40)	116 (41)	354 (40)
Taking aspirin				
Yes, n (%)	2 (1)	1 (0)	2 (1)	5 (1)

Missing, n (%)	0 (0)	0 (0)	0 (0)	0 (0)
Time from onset of symptoms to hospitalisation				
Median (IQR)	4 (2, 6)	4 (2, 6)	4 (2, 6)	4 (2, 6)
Time from hospitalisation to randomisation				
Median (IQR)	1 (1, 2)	2 (1, 3)	1 (1, 2)	1 (1, 2)
D-dimer				
Test performed, n(%)	254 (85)	258 (87)	247 (87)	759 (86)
Out of range, n(%)	77 (30)	66 (26)	63 (26)	206 (27)

¹ For APTT, INR, Fibrinogen, and Prothrombin only at least one required.

Table 3.8: Baseline prognostics for participants included in ACS-ITT-therapeutic

Variable	Anticoagulation			Overall (n = 194)
	Low dose (n = 79)	Intermediate dose (n = 65)	Therapeutic dose (n = 50)	
Was the patient on room air for any of the preceding 24 hours?				
Yes, n (%)	61 (77)	48 (74)	39 (78)	148 (76)
Missing, n (%)	0 (0)	0 (0)	0 (0)	0 (0)
Was the patient's GCS < 15?				
Yes, n (%)	1 (1)	3 (5)	2 (4)	6 (3)
Missing, n (%)	0 (0)	0 (0)	0 (0)	0 (0)
Peripheral oxygen saturation (SpO2) on room air (Lowest)				
Median (IQR)	94 (89, 95)	92 (86, 96)	94 (92, 96)	94 (89, 96)
Missing, n (%)	18 (23)	17 (26)	11 (22)	46 (24)
Highest respiratory rate (breaths/minute)				
Median (IQR)	22 (20, 24)	22 (20, 24)	22 (20, 24)	22 (20, 24)
Missing, n (%)	0 (0)	1 (2)	0 (0)	1 (1)
Highest recorded Urea in the last 24 hours (mmol/L)				
Median (IQR)	4 (3, 6)	5 (3, 6)	4 (3, 6)	4 (3, 6)
Missing, n (%)	1 (1)	0 (0)	1 (2)	2 (1)
Highest recorded CRP in the last 24 hours (mg/L)				
Median (IQR)	38 (7, 83)	37 (14, 80)	68 (33, 129)	51 (9, 98)
Missing, n (%)	51 (65)	31 (48)	29 (58)	111 (57)
APTT¹				
Median (IQR)	32 (28, 36)	31 (28, 36)	33 (28, 38)	32 (28, 36)
Missing, n (%)	57 (72)	34 (52)	35 (70)	126 (65)
INR¹				
Mean (SD)	1.14 (0.28)	1.07 (0.12)	1.12 (0.18)	1.11 (0.21)
Missing, n (%)	5 (6)	5 (8)	7 (14)	17 (9)

Fibrinogen¹ (g/L)				
Mean (SD)	6.49 (1.94)	5.46 (2.01)	6.49 (1.52)	6.01 (1.93)
Missing, n (%)	65 (82)	46 (71)	42 (84)	153 (79)
Prothrombin time¹ (sec)				
Median (IQR)	13 (12, 14)	13 (12, 14)	13 (12, 14)	13 (12, 14)
Missing, n (%)	10 (13)	15 (23)	10 (20)	35 (18)
Taking aspirin				
Yes, n (%)	3 (4)	7 (11)	3 (6)	13 (7)
Missing, n (%)	0 (0)	0 (0)	0 (0)	0 (0)
Time from onset of symptoms to hospitalisation				
Median (IQR)	6 (3, 8)	5 (3, 6)	4 (3, 6)	5 (3, 7)
Time from hospitalisation to randomisation				
Median (IQR)	1 (1, 1)	1 (1, 2)	1 (1, 1)	1 (1, 1)
D-dimer				
Test performed, n(%)	22 (28)	25 (38)	17 (34)	64 (33)
Out of range, n(%)	13 (59)	14 (56)	10 (59)	37 (58)

¹ For APTT, INR, Fibrinogen, and Prothrombin only at least one required.

Table 3.9: Baseline prognostics for participants who were not part of ACS-ITT-aspirin or ACS-ITT-therapeutic.

Variable	Anticoagulation		Overall (n = 482)
	Low-dose (n = 232)	Intermediate-dose (n = 250)	
Was the patient on room air for any of the preceding 24 hours?			
Yes, n (%)	155 (67)	180 (72)	335 (70)
Missing, n (%)	0 (0)	1 (0)	1 (0)
Was the patient's GCS < 15?			
Yes, n (%)	58 (25)	59 (24)	117 (24)
Missing, n (%)	50 (22)	60 (24)	110 (23)
Peripheral oxygen saturation (SpO2) on room air (Lowest)			
Median (IQR)	96 (94, 97)	96 (95, 97)	96 (94, 97)
Missing, n (%)	77 (33)	70 (28)	147 (30)
Highest respiratory rate (breaths/minute)			
Median (IQR)	24 (22, 26)	24 (22, 26)	24 (22, 26)
Missing, n (%)	0 (0)	0 (0)	0 (0)
Highest recorded Urea in the last 24 hours (mmol/L)			
Median (IQR)	4 (4, 5)	4 (4, 6)	4 (4, 6)
Missing, n (%)	12 (5)	10 (4)	22 (5)
Highest recorded CRP in the last 24 hours (mg/L)			

Median (IQR)	72 (40, 193)	75 (43, 225)	72 (42, 203)
Missing, n (%)	8 (3)	11 (4)	19 (4)
APTT¹			
Median (IQR)	33 (31, 36)	34 (32, 35)	33 (31, 36)
Missing, n (%)	187 (81)	200 (80)	387 (80)
INR¹			
Mean (SD)	1.26 (0.54)	1.31 (0.59)	1.29 (0.57)
Missing, n (%)	57 (25)	53 (21)	110 (23)
Fibrinogen¹ (g/L)			
Mean (SD)	5.60 (0.93)	5.60 (1.19)	5.60 (1.06)
Missing, n (%)	222 (96)	236 (94)	458 (95)
Prothrombin time¹ (sec)			
Median (IQR)	16 (13, 19)	15 (13, 19)	15 (13, 19)
Missing, n (%)	64 (28)	70 (28)	134 (28)
Taking aspirin			
Yes, n (%)	15 (6)	17 (7)	32 (7)
Missing, n (%)	0 (0)	0 (0)	0 (0)
Time from onset of symptoms to hospitalisation			
Median (IQR)	5 (4, 6)	5 (4, 7)	5 (4, 7)
Time from hospitalisation to randomisation			
Median (IQR)	0 (0, 2)	1 (0, 2)	1 (0, 2)
D-dimer			
Test performed, n(%)	218 (94)	231 (92)	449 (93)
Out of range, n(%)	92 (42)	97 (42)	189 (42)

¹ For APTT, INR, Fibrinogen, and Prothrombin only at least one required.